		Item-test correlation

N∘	Item	Cognitive scale	Affective scale

1	Her/his parents’ or siblings’ emotions don’t affect her/him much		0.20

2	After being with a relative who is sad about something, s/he usually feels sad		0.40

4	S/he gets frightened when s/he watches characters in a good scary movie		0.32

5	S/he gets caught up in other people’s feelings easily		0.52

7	S/he doesn’t become sad when he/she sees other people crying		0.42

8	Other people’s feelings don’t bother her/him at all		0.47

11	S/he often becomes sad when watching sad things on TV or in films		0.50

13	Seeing a person who has been angered has no effect on her/his feelings		0.40

15	S/he tends to feel scared when s/he is with friends or relatives who are afraid		0.23

17	S/he often gets swept up in her/his siblings’ or friend’s feelings		0.39

18	Her/his relatives or friend’s unhappiness doesn’t make her/him feels anything		0.48

3	S/he can understand her/his friend’ or relative’s happiness when that person does well at something	0.38

6	S/he finds it hard to know when other children are frightened	0.18

9	When someone is feeling ‘down’ s/he can usually understand how that person feels	0.56

10	S/he can usually work out when other children are scared	0.50

12	S/he can often understand how people are feeling even before they tell her/him	0.46

14	S/he can usually work out when people are cheerful	0.48

16	S/he can usually realize quickly when either of her/his parents is angry	0.37

19	S/he is not usually aware of her/his loved ones’ feelings	0.47

20	S/he has trouble figuring out when other members of the family are happy	0.42


Diagnosis category	Number of missions

Cardiac arresta	2

Acute coronary syndrome	6

Circulatory emergencyb	6

Respiratory emergency	2

Trauma	8

Neurological emergency	3

Gastrointestinal emergency	5

Other emergency	3


Trait	Variance (%)

α-Amylase	52.2

Diastatic power	74.1

Malt extract	54.0

Heading date	70.4

Plant height	64.2

Lodging	40.3

Grain protein content	45.6

Yield	22.4

Trait	Variance (%)

Heading date	70.4

Plant height	64.2

Lodging	40.3

Grain protein content	45.6

Yield	22.4


Project and Timeline	General Objective	Study Sites	Consortium partners

CERCA1/03/10 –29/02/14	To contribute to global knowledge about how health systems can be more responsive to the sexual and reproductive health needs of adolescents and, by extension, to other health needs of Latin American populations.	City of Cuenca (Ecuador)City of Managua (Nicaragua)City of Cochabamba (Bolivia)	South Group (Bolivia), University of Cuenca (Ecuador), Lithuanian University of Health Sciences (Lithuania), Amsterdam University (The Netherlands), Centro de Investigaciones y Estudios de Salud (Nicaragua), Instituto Centro Americano de Salud (Nicaragua)

DIFFER1/10/11 –30/09/16	To improve sexual and reproductive health for all women by expanding and strengthening sexual and reproductive health services, and providing and testing targeted interventions for female sex workers in the context of existing health systems.	Mombasa County, Coastal Province (Kenya)Cities of Tete and Moatize, Tete Province (Mozambique)City of Durban (eThekwini District), KwaZulu-Natal Province (South Africa)City of Mysore, Karnataka State (India)	Ashodaya Samithi (India), International Centre for Reproductive Health Association (Kenya), International Centre for Reproductive Health Association (Mozambique), University of the Witwatersrand – MatCH (South Africa), University College London – Institute for Global Health (United Kingdom)

INPAC1/08/12 –31/07/16	To evaluate the effectiveness of introducing integrated post-abortion family planning services into existing hospital-based abortion services in China in order to reduce unintended pregnancies and repeated abortions.	30 of 31 provinces, municipalities and autonomous regions of mainland China	Chinese Society of Family Planning – Chinese Medical Association (China), Fudan University (China), National Research Institute for Family Planning (China), West China Second University Hospital of Sichuan University (China), University of Aarhus – Danish Epidemiology Science Centre (Denmark), Liverpool School of Tropical Medicine (United Kingdom)

MOMI1/02/11 –31/01/16	To improve maternal and newborn health through a focus on the postpartum period, adopting context-specific strategies to strengthen health care delivery and services at both facility and community level in four sub-Saharan countries.	Kaya District (Burkina Faso)Kwale District (Kenya)Ntchisi District (Malawi)Chiuta District (Mozambique)	Institut de Recherche en Sciences de la Santé (Burkina Faso), International Centre for Reproductive Health Association (Kenya), Faculdade de Medicina – Eduardo Mondlane University (Mozambique), International Centre for Reproductive Health Association (Mozambique), Parent and Child Health Initiative (Malawi), Faculdade de Medicina da Universidade do Porto – Department of Hygiene and Epidemiology (Portugal), University College London – Institute for Global Health (United Kingdom)

Project and Timeline	General Objective	Study Sites	Consortium partners

MOMI1/02/11 –31/01/16	To improve maternal and newborn health through a focus on the postpartum period, adopting context-specific strategies to strengthen health care delivery and services at both facility and community level in four sub-Saharan countries.	Kaya District (Burkina Faso)Kwale District (Kenya)Ntchisi District (Malawi)Chiuta District (Mozambique)	Institut de Recherche en Sciences de la Santé (Burkina Faso), International Centre for Reproductive Health Association (Kenya), Faculdade de Medicina – Eduardo Mondlane University (Mozambique), International Centre for Reproductive Health Association (Mozambique), Parent and Child Health Initiative (Malawi), Faculdade de Medicina da Universidade do Porto – Department of Hygiene and Epidemiology (Portugal), University College London – Institute for Global Health (United Kingdom)


Characteristics	Number of patients (%)

Sex

Male	107 (81.7)

Female	24 (18.3)

Age

≤64	57 (43.5)

>64	74 (56.5)

Smoking

Smoking index >400	41 (31.3)

Smoking index ≤400	36 (27.5)

No	54 (41.2)

Grade

Low	60 (45.8)

High	71 (54.2)

Invasiveness

Muscle-invasive	72 (55.0)

Non-muscle-invasive	59 (45.0)

Relapse

Yes	90 (68.7)

No	41 (31.3)

Metastasis

Yes	20 (15.3)

No	111 (84.7)

Characteristics	Number of patients (%)

Grade

Low	60 (45.8)

High	71 (54.2)

Invasiveness

Muscle-invasive	72 (55.0)

Non-muscle-invasive	59 (45.0)

Relapse

Yes	90 (68.7)

No	41 (31.3)

Metastasis

Yes	20 (15.3)

No	111 (84.7)


	Gene	Alteration	RsID	COSMIC

Sample 1	ARID1A	Gln1614*	NR	NR

Sample 1	NOTCH1	N280S	rs367825691	NR

Sample 1	PIK3CA	EDLLNPI453del	NR	NR

Sample 1	ROS1	V1881_splice	rs772648589	NR

Sample 2	ARID1A	P476*	NR	NR

Sample 2	ARID1A	Leu1054Phe	NR	NR

Sample 2	KMT2D	Gln3745dup	rs775492040	NR

Sample 3	CDKN2Aa	Glu69*	rs121913383	COSM13281

Sample 3	TP53a	Asn268*	NR	COSM6583

Sample 4	TP53	Arg181Cys	rs587782596	COSM11090

Sample 5	KRAS	Gly12Val	rs121913529	COSM520

Sample 5	PIK3CA	His1047Arg	rs121913279	COSM775

Sample 6	ALK	Gly926Arg	NR	NR

Sample 6	ERBB2	Ile989Met	NR	NR

Sample 7	ARID1Aa	Tyr1055*	NR	NR

Sample 7	PIK3CAa	Lys111Glu	NR	COSM13570

Sample 8	SPOP	Lys115Glu	NR	NR

Sample 9	ARID1A	Gln537*	NR	NR

Sample 9	ARID1A	Gln2176*	NR	COSM1582021

Sample 9	PIK3CA	His1047Arg	rs121913279	COSM775

	Gene	Alteration	RsID	COSMIC

Sample 2	ARID1A	Leu1054Phe	NR	NR

Sample 2	KMT2D	Gln3745dup	rs775492040	NR

Sample 3	CDKN2Aa	Glu69*	rs121913383	COSM13281

Sample 3	TP53a	Asn268*	NR	COSM6583

Sample 4	TP53	Arg181Cys	rs587782596	COSM11090

Sample 5	KRAS	Gly12Val	rs121913529	COSM520

Sample 5	PIK3CA	His1047Arg	rs121913279	COSM775

Sample 6	ALK	Gly926Arg	NR	NR

Sample 6	ERBB2	Ile989Met	NR	NR

Sample 7	ARID1Aa	Tyr1055*	NR	NR

Sample 7	PIK3CAa	Lys111Glu	NR	COSM13570

Sample 8	SPOP	Lys115Glu	NR	NR

Sample 9	ARID1A	Gln537*	NR	NR

Sample 9	ARID1A	Gln2176*	NR	COSM1582021

Sample 9	PIK3CA	His1047Arg	rs121913279	COSM775


	Native	Derivative

Data collection

 Beamline	ESRF ID14-4	SLS X06DA (PXIII)

 Spacegroup	P3	P3

 Unit cell parameters (Å, °)	a = b = 104.50, c = 33.59	a = b = 104.03, c = 33.56

 	α = β = 90, γ = 120	α = β = 90, γ = 120

 Wavelength (Å)	0.91970	0.97942

 Resolution limits (Å)	52.25–1.49 (1.54–1.49)*	31.45–2.00 (2.06–2.00)*

 Reflections observed/unique	607786/64606	419456/27271

 Completeness (%)	98.3 (96.3)*	99.9 (98.9)*

 Rsym†(%)	5.6 (36.1)*	9.4 (75.2)*

 <I>/<σI>	26.3 (6.4)*	24.1 (3.9)*

 Redundancy	9.4 (8.8)*	15.4 (13.9)*

SAD phasing

 BAYES-CC		49.1 ± 18.5

 Se sites found/expected		5/6

 FOM before solvent flattening and density modification		0.35

 FOM after solvent flattening and density modification		0.69

Refinement

 Resolution limits (Å)	52.25–1.49 (1.52–1.49)*

 Reflections for Rcryst/for Rfree	59806/4800

 Rcryst‡(%)	12.4 (20.6)*

 Rfree‡(%)	16.4 (23.0)*

 No. of protein atoms/water atoms	2307/297

 Average B factor protein atoms/water atoms (Å2)	21.67/35.34

 RMSD bond lengths (Å)	0.005

 RMSD bond angles (°)	0.854

 Twin fraction (operator −h, −k, l)	0.49

Ramachandran Plot Statistics§

 Favoured region (%)	99.3

 Outliers (%)	0.0

	Native	Derivative

Unit cell parameters (Å, °)	a = b = 104.50, c = 33.59	a = b = 104.03, c = 33.56

	α = β = 90, γ = 120	α = β = 90, γ = 120

Wavelength (Å)	0.91970	0.97942

Resolution limits (Å)	52.25–1.49 (1.54–1.49)*	31.45–2.00 (2.06–2.00)*

Reflections observed/unique	607786/64606	419456/27271

Completeness (%)	98.3 (96.3)*	99.9 (98.9)*

Rsym†(%)	5.6 (36.1)*	9.4 (75.2)*

/<σI>	26.3 (6.4)*	24.1 (3.9)*

Redundancy	9.4 (8.8)*	15.4 (13.9)*

SAD phasing

BAYES-CC		49.1 ± 18.5

Se sites found/expected		5/6

FOM before solvent flattening and density modification		0.35

FOM after solvent flattening and density modification		0.69

Refinement

Resolution limits (Å)	52.25–1.49 (1.52–1.49)*

Reflections for Rcryst/for Rfree	59806/4800

Rcryst‡(%)	12.4 (20.6)*

Rfree‡(%)	16.4 (23.0)*

No. of protein atoms/water atoms	2307/297

Average B factor protein atoms/water atoms (Å2)	21.67/35.34

RMSD bond lengths (Å)	0.005

RMSD bond angles (°)	0.854

Twin fraction (operator −h, −k, l)	0.49

Ramachandran Plot Statistics§

Favoured region (%)	99.3

Outliers (%)	0.0


Genetics	Mechanism	Incidence	Reference

Ptch+/−	Conventional KO	14%–19% by 10 months	(23, 44, 98)

Ptch+/−	Conventional KO; irradiation	100% by 10 months	(54, 55)

Ptch+/−; p53−/−	Conventional KO	100% by 2–3 months	(89)

Ptch+/−; Ptch2±/−	Conventional KO	17% by 10 months	(44)

Ptch+/−	Conditional KO (GFAP-Cre, Math1-Cre)	100% by 1–3 months	(95)

ND2-SmoA1	TG	94% by 2 months	(26, 28)

SmoM2	Conditional TG (GFAP-Cre, Math1-Cre, Olig2-Cre, Tlx-Cre)	100% by 2–4 months*	(69)

Sufu+/−; p53−/−	Conventional KO	58% by 10 months	(42)

Shh	RCAS	9%–34% by 3 months	(7, 49, 60, 61)

Shh; c-myc/Akt/IGF2	RCAS	23%–48% by 3 months	(60, 61)

Shh; n-myc	RCAS	78% by 3 months	(7)

Shh; Bcl-2	RCAS	78% by 3 months	(49)

Rb±/−; p53−/−	Conditional KO (GFAP-Cre)	25%–100% by 2–7 months	(48)

Ink4c±/−; p53±/−	Conventional and conditional KO (Nestin-Cre); irradiation	20%–100% by 5 months	(81)

Ptch+/−; Ink4c±/−	Conventional KO	40%–50% by 9 months	(81)

Lig4−/−; p53−/−	Conventional KO	100% by 2 months	(43)

Brca2−/−; p53±/−	Conventional and conditional KO (Nestin-Cre)	72%–83% by 4–8 months	(17)

Xrcc4−/−; p53−/−	Conventional and conditional KO (Nestin-Cre)	100% by 6 months	(94)

Genetics	Mechanism	Incidence	Reference

Ptch+/−	Conventional KO	14%–19% by 10 months	(23, 44, 98)

Ptch+/−	Conventional KO; irradiation	100% by 10 months	(54, 55)

Ptch+/−; p53−/−	Conventional KO	100% by 2–3 months	(89)

Ptch+/−; Ptch2±/−	Conventional KO	17% by 10 months	(44)

Ptch+/−	Conditional KO (GFAP-Cre, Math1-Cre)	100% by 1–3 months	(95)

ND2-SmoA1	TG	94% by 2 months	(26, 28)

SmoM2	Conditional TG (GFAP-Cre, Math1-Cre, Olig2-Cre, Tlx-Cre)	100% by 2–4 months*	(69)

Sufu+/−; p53−/−	Conventional KO	58% by 10 months	(42)

Shh	RCAS	9%–34% by 3 months	(7, 49, 60, 61)

Shh; c-myc/Akt/IGF2	RCAS	23%–48% by 3 months	(60, 61)

Shh	RC	78% by 3 mont	(

Genetics	Mechanism	Incidence	Reference

; n-myc	AS	hs	7)

Shh; Bcl-2	RCAS	78% by 3 months	(49)

Rb±/−; p53−/−	Conditional KO (GFAP-Cre)	25%–100% by 2–7 months	(48)

Ink4c±/−; p53±/−	Conventional and conditional KO (Nestin-Cre); irradiation	20%–100% by 5 months	(81)

Ptch+/−; Ink4c±/−	Conventional KO	40%–50% by 9 months	(81)

Lig4−/−; p53−/−	Conventional KO	100% by 2 months	(43)

Brca2−/−; p53±/−	Conventional and conditional KO (Nestin-Cre)	72%–83% by 4–8 months	(17)

Xrcc4−/−; p53−/−	Conventional and conditional KO (Nestin-Cre)	100% by 6 months	(94)


Input variables	Unit cost (£)	Source	Details

Interventions

 Lens extraction implemented as day case	866	National schedule of reference costs year 2012–2013	Phacoemulsification cataract extraction and lens implant implemented as day case (BZ02)

 Lens extraction implemented as inpatient	2157	National schedule of reference costs year 2012–2013	Phacoemulsification cataract extraction and lens implant implemented as inpatient (BZ02)

 Laser iridotomy implemented as outpatient	118	National schedule of reference costs year 2012–2013	Laser iridotomy (minor glaucoma procedures implemented as outpatient (BZ19))

Subsequent procedures

 Lens capsulotomy	121	National schedule of reference costs year 2012–2013	Lens capsulotomy (BZ04) implemented as outpatient

 Iridoplasty	172	National schedule of reference costs year 2012–2013	Major glaucoma procedures implemented as outpatient (BZ17)

 Trabeculectomy	1140	National schedule of reference costs year 2012–2013	Intermediate glaucoma procedures implemented as day case (BZ18)

 Cataract surgery	866	National schedule of reference costs year 2012–2013	Phacoemulsification cataract extraction and lens implant implemented as day case (BZ02)

Primary healthcare

 General practitioner visit	43	PSSRU 2013	Community-based healthcare staff

 General practitioner visit at home	53.58	PSSRU 2013	Community-based healthcare staff

 General practitioner telephone conversation	26	PSSRU 2013	Community-based healthcare staff

 Community optician and optometrist	62	National schedule of reference costs year 2012–2013	Follow-up attendance—non-consultant led outpatient attendances

 District nurse	12.40	PSSRU 2013	Community-based healthcare staff

 Practice nurse	10.59	PSSRU 2013	Community-based healthcare staff

 Clinical support worker nursing (community)	31	PSSRU 2013	Community-based healthcare staff

Secondary healthcare

 Ophthalmologist visit	80	National schedule of reference costs year 2012–2013	Consultant-led outpatient attendances, follow-up

Input variables	Unit cost (£)	Source	Details

Interventions

Lens extr		Nati	Phacoemulsification cataract extraction and

Input variables	Unit cost (£)	Source	Details

action implemented as day case	866	onal schedule of reference costs year 2012–2013	lens implant implemented as day case (BZ02)

Lens extraction implemented as inpatient	2157	National schedule of reference costs year 2012–2013	Phacoemulsification cataract extraction and lens implant implemented as inpatient (BZ02)

Laser iridotomy implemented as outpatient	118	National schedule of reference costs year 2012–2013	Laser iridotomy (minor glaucoma procedures implemented as outpatient (BZ19))

Subsequent procedures

Lens capsulotomy	121	National schedule of reference costs year 2012–2013	Lens capsulotomy (BZ04) implemented as outpatient

Iridoplasty	172	National schedule of reference costs year 2012–2013	Major glaucoma procedures implemented as outpatient (BZ17)

Trabeculectomy	1140	National schedule of reference costs year 2012–2013	Intermediate glaucoma procedures implemented as day case (BZ18)

Cataract surgery	866	National schedule of reference costs year 2012–2013	Phacoemulsification cataract extraction and lens implant implemented as day case (BZ02)

Primary healthcare

General practitioner visit	43	PSSRU 2013	Community-based healthcare staff

General practitioner visit at home	53.58	PSSRU 2013	Community-based healthcare staff

General practitioner telephone conversation	26	PSSRU 2013	Community-based healthcare staff

Community optician and optometrist	62	National schedule of reference costs year 2012–2013	Follow-up attendance—non-consultant led outpatient attendances

District nurse	12.40	PSSRU 2013	Community-based healthcare staff

Practice nurse	10.59	PSSRU 2013	Community-based healthcare staff

Clinical support worker nursing (community)	31	PSSRU 2013	Community-based healthcare staff

Secondary healthcare

Ophthalmologist visit	80	National schedule of reference costs year 2012–2013	Consultant-led outpatient attendances, follow-up


Variable	Beta	Standard error	Significance (p value)

toeC	−0.197	0.058	0.001


 	Total (n = 149)

Mean age ± SD, range	38.95 ± 11.48, 20-77

Years in the US ± SD	10.24 ± 10.12

Years in Baltimore ± SD	7.56 ± 9.09

Gender

Female	(98) 65.7%

Male	(51) 34.3%

Latin American Region

Mexican	(38) 25.5%

Central American	(87) 58.4%

South American	(24) 16.1%

Education (n = 146)

None	(8) 5.48%

Less than 8 years	(80) 54.79%

Some High School	(19) 13.01%

High School Graduate	(15) 10.27%

Some College	(16) 10.96%

Completed college or

higher	(8) 5.48%

Food security

No food insecurity	(74) 49.66%

Some risk for food

insecurity	(15) 10.07%

Moderate food insecurity at the household level	(31) 20.81%

Food insecure with some hunger at the household level	(29) 19.46%

BMI <30 kg/m2	(89) 59.73%

BMI >30 kg/m2	(60) 40.27%

Mean age ± SD, range

Years in the US ± SD

Years in Baltimore ± SD

Gender

Female

Male

Latin American Region

Mexican

Central American

South American

Education (n = 146)

None

Less than 8 years

Some High School

High School Graduate

Some College

Completed college or

higher

Food security

No food insecurity

Some risk for food

insecurity

Moderate food insecurity at the household level

Food insecure with some hunger at the household level

BMI <30 kg/m2

BMI >30 kg/m2


Substance	No. of cases	Percentage

Hydrofluoric acid	135	27.44

Sulfuric acid	115	23.37

Mixed acid	41	8.33

Sodium (potassium) hydroxide	33	6.71

Nitric acid	31	6.30

Hydrochloric acid	27	5.49

Lye	18	3.66

Phenol	14	2.85

Calcium oxide	11	2.24

Bromine	10	2.03

Bitumen	8	1.63

Acetic acid	7	1.42

Liquid ammonia	7	1.42

Aromatic amino and nitro compounds	6	1.22

Dimethyl sulfate	5	1.02

m-cresol	4	0.81

Yellow phosphorous	4	0.81

Others	16	3.25

Substance	No. of cases

Hydrofluoric acid	135

Sulfuric acid	115

Mixed acid	41

Sodium (potassium) hydroxide	33

Nitric acid	31

Hydrochloric acid	27

Lye	18

Phenol	14

Calcium oxide	11

Bromine	10

Bitumen	8

Acetic acid	7

Liquid ammonia	7

Aromatic amino and nitro compounds	6

Dimethyl sulfate	5

m-cresol	4

Yellow phosphorous	4

Others	16


	Total Group (n = 1526) 1	10–11 Months (n = 31)	1 Year (n = 411)

Food Group	Mean	SD	Mean	SD	Mean	SD

Potatoes	29	27	25	25	31	28

Vegetables	58	39	48	45	60	41

Fruit	128	59	129	66	127	58

Legumes	1	7	1	4	2	9

Bread	100	35	57	29	86	33

Cereals (including rice and pasta)	29	29	21	26	30	30

Cakes and biscuits	13	12	6	8	11	10

Nuts, seeds, savory snacks	1	5	0	0	1	3

Milk and milk products	358	158	176	217	333	162

Follow-on and young children’s formula	63	135	411	226	111	162

Cheese	14	11	14	10	15	11

Eggs	3	8	1	4	2	7

Fish	5	12	2	7	5	12

Meat, meat products, poultry	44	25	24	23	40	24

Soy and vegetarian products	8	49	0	2	8	54

Savory spreads	4	6	0	0	3	6

Mixed dishes	20	45	52	78	28	53

Soups	10	33	0	1	6	23

Sugar, confectionary, sweet spreads	18	13	6	7	13	10

Fat spreads, oils, savory sauces	24	11	11	8	20	10

Non-alcoholic beverages (excluding milk products)	427	222	182	145	367	204


Variable

Sex [no. (%)] n = 634

Female	388 (61.2)

Age [mean: years (SD)] n = 634	56.30 (13.95)

Nationality [no. (%)] n = 619

German	610 (98.5)

Other	9 (1.5)

Marital status [no. (%)] n = 634

Single	82 (12.9)

Married	415 (65.5)

Divorced	80 (12.6)

Widowed	57 (9.0)

Living with a partner [no. (%)] n = 611	477 (78.1)

Persons at household [no. (%)] n = 605

1 person	87 (14.4)

2 persons	297 (49.1)

3 persons	114 (18.8)

4 persons	74 (12.2)

> 4 persons	33 (5.4)

Level and years of education [no. (%)] n = 632

13/12 years	100 (15.8)

10 years	191 (30.2)

9 years	322 (50.9)

Other graduation	15 (2.4)

No qualification	4 (0.6)

Employment status [no. (%)] n = 631

Working (full or part-time)	322 (51.0)

Reasons for not working [no. (%)] n = 306

Keeping house	48 (15.7)

Retired	228 (74.6)

Unemployed	27 (8.8)

Other	3 (1.0)

First time of back pain [no (%)] n = 634

Since < 1 year	77 (12.2)

Since 1-2 years	47 (7.4)

Since 2-5 years	86 (13.6)

Since 5-10 years	92 (14.5)

Since > 10 years	332 (52.4)

Variable

Sex [no. (%)] n = 634

Female

Age [mean: years (SD)] n = 634

Nationality [no. (%)] n = 619

German

Other

Marital status [no. (%)] n = 634

Single

Married

Divorced

Widowed

Living with a partner [no. (%)] n = 611

Persons at household [no. (%)] n = 605

1 person

2 persons

3 persons

4 persons

> 4 persons

Level and years of education [no. (%)] n = 632

13/12 years

10 years

9 years

Other graduation

No qualification

Employment status [no. (%)] n = 631

Working (full or part-time)

Reasons for not working [no. (%)] n = 306

Keeping house

Retired

Unemployed

Other

First time of back pain [no (%)] n = 634

Since < 1 year

Since 1-2 years

Since 2-5 years

Since 5-10 years

Since > 10 years


Group	No of casesa(Females)	Age (years) median; 80% CRb	Marsh grade span	Anti-TG2 (U/mL)cmedian; 80% CR	Anti-DGP (U/mL)dmedian; 80% CR	Anti-GL (U/mL)emedian; 80% CR

Active CDg	20 (12)	5.9; 1.5-14	Marsh 2-3C	201; 4.4-1997	64; 5.6-392	16; 2.4-167

Under investigationh	3 (3)	15; 12-16	Marsh 0-1	15; 10-16	7.1; 2.1-22	1.9; 0.50-6.5


Sample Name	N-Call stretch lengths (bp)	Mutation found by conventional sequencing

	*GSEQ	*sPROFILER

mtDNA1	5, 6, 9, 13	4, 5	1 point mutation (in 5 base stretch)

mtDNA2	5, 6, 12	4, 5, 6	1 point mutation (in 6 base stretch)

mtDNA3	5, 6, 7, 11	4, 10	1 point mutation, 1 insertion (in 10 base stretch)

mtDNA4	5, 6, 11	4, 5	1 insertion (in 5 base stretch)

mtDNA5	5, 13	4, 5	1 insertion (in 5 base stretch)

mtDNA6	5, 7, 11	4, 5, 11	1 point mutation, 1 insertion (in 11 base stretch)

mtDNA7	5, 10	4	Entire mtDNA sequenced: 1 point mutation(in 4 N-call stretch)

mtDNA8	5, 6, 8, 9, 10, 11, 14, 18, 20	4, 5, 6, 8, 10,18, 20	1 point mutation (in 20 base stretch)2 point mutations (in 18 base stretch)1 point mutation (in 10 base stretch)

mtDNA9	5, 6, 9, 11, 12	4, 5, 8	2 insertions (in 8 base stretch)

mtDNA10	5, 7, 8, 9, 10	4, 5, 7, 9	1 point mutation (in 9 base stretch)

mtDNA11	5, 6, 8, 9, 12	4, 5, 8	1 point mutation (in 8 base stretch)

mtDNA12	5, 9, 10	4, 9	1 insertion (in 9 base stretch)

mtDNA13	5, 7, 8, 9, 10	4, 5, 9	1 point mutation (in 9 base stretch)

mtDNA14	5, 8, 10	4, 5	No point mutation or indel (in 5 base stretch)

mtDNA15	5, 6, 7, 11	4, 5	No point mutation or indel (in 5 base stretch)

mtDNA16	5, 7, 8, 10, 11	4, 6	No point mutation or indel (in 6 base stretch)


Country	VTE patients %	General healthy population %	References

Lebanon	19.2	1.3–3.6	94–99

Palestine	---	6.5–11.7	74,100

Egypt	23.75	3.33	101

Tunisia	3.2	0–7.4	74,79–99,102–105

Libya	---	2.2	74

Alg	6		1


Spot No.	Protein Identity	Symbol	MW (kDa)

1	Aldehyde dehydrogenase,mitochondrial precursor	Aldh2	56

2	Protein disulfide-isomerase A3precursor	Pdia3/ERP57	57

3	Proteasome subunit alpha type 6	Psma6	27

4	Peptidyl-prolyl cis-transisomerase A	Ppia/CYPA	17

Spot No.	Protein Identity	Symbol	MW (kDa)

1	Aldehyde dehydrogenase,mitochondrial precursor	Aldh2	56

2	Protein disulfide-isomerase A3precursor	Pdia3/ERP57	57

3	Proteasome subunit alpha type 6	Psma6	27

	Pept	Ppia	1

Spot No.	Protein Identity	Symbol	MW (kDa)

4	idyl-prolyl cis-transisomerase A	/CYPA	7


Criteria	Conventional	Sutureless

Operation duration	Longer	Shorter

Blood less during operation	More probable	Less probable

Safe and reliable	Less probable	More probable

Resistance of anastomosis (mechanical and pressure testing)	Less probable	More probable

Operative and post-operative complications	More probable	Less probable

Stress of surgeon and patient	More	Less

Reduce the cost of treatment	More	Less


Institution	Checklists

Step 1	Step 2	Step 3	Step 4	Step 5	Step 6	Step 7

A			4	1		2	2

B			3		1	2	5

C			1	2			1

D	1	1	2	1	2	2	4

E			3		4	3	3

F							3

G	2	2	2	2	4	4	5

Total number of failure cases at each checklist	3	3	15	6	11	13	23

Institution	Checklists

Step 1	Step 2	Step 3	Step 4	Step 5	Step 6	Step 7

F							3

G	2	2	2	2	4	4	5

Total number of failure cases at each checklist	3	3	15	6	11	13	23


No	Preparation	Dosage from	Trade name / Manufacturer	Dissolution time (mins, n=3)

pH 1.2	pH 5.8

1	Ferrous sulphate	Tablet	NAAlmus	48 ± 4	362 ± 16

2	Ferrous fumarate	Tablet	FersamalGoldshield	57 ± 6	85 ± 9

3	Ferrous gluconate	Tablet	NAZanza	64 ± 4	208 ± 12

4	Ferrous sulphate plus ascorbic acid	Controlled release tablet	Ferrograd CTeopharma	256 ± 8	–

5	Ferrous fumarate plus minerals and vitamins	Sustained release capsule	Ferroglobin B12Vitabiotics	274 ± 8	388 ± 11

No	Preparation	Dosage from	Trade name / Manufacturer	pH 1.2	pH 5.8

1	Ferrous sulphate	Tablet	NAAlmus	48 ± 4	362 ± 16

2	Ferrous fumarate	Tablet	FersamalGoldshield	57 ± 6	85 ± 9

3	Ferrous gluconate	Tablet	NAZanza	64 ± 4	208 ± 12

4	Ferrous sulphate plus ascorbic acid	Controlled release tablet	Ferrograd CTeopharma	256 ± 8	–

5	Ferrous fumarate plus minerals and vitamins	Sustained release capsule	Ferroglobin B12Vitabiotics	274 ± 8	388 ± 11


	Multiple Sexual Partners	Paying Sex

	n	%	n	%

Used condom	384	33.9	469	58.5

Did not use condom	748	66.1	333	41.5

Multiple Sexual Partners	Paying Sex

n	%	n	%

384	33.9	469	58.5

748	66.1	333	41.5


Items	1) Basic science content objectives were made clear to students	2) Basic science content was sufficiently integrated across basic science courses	3) Basic science content objectives and examination content matched closely	4) Basic science content had sufficient illustrations of clinical relevance	5) Basic science content provided relevant preparation for clerkships

% of agree	TC	57.9	37.9	56.6	43.4	65.5

RC	78.8	72.7	81.8	69.7	72.7

TC	Mean	3.48	3.20	3.46	3.26	3.64

SD	0.973	0.925	0.936	0.993	0.926

RC	Mean	4.03	3.91	4.03	3.85	3.91

SD	0.770	0.843	0.728	0.906	0.843

U (p)	*1,657.5 (0.003)	*1,401.5 (<0.0001)	*1,587.5(0.001)	*1,616.5(0.002)	2,041.0(0.153)

Cohen’s d	−0.627	−0.802	−0.680	−0.621	−0.305

Items

% of agree

TC

RC

U (p)

Cohen’s d

Items	1) Basic science content objectives were made clear to students	2) Basic science content was sufficiently integrated across basic science courses	3) Basic science content objectives and examination content matched closely	4) Basic science content had sufficient illustrations of clinical relevance	5) Basic science content provided relevant preparation for clerkships

TC	57.9	37.9	56.6	43.4	65.5

RC	78.8	72.7	81.8	69.7	72.7

Mean	3.48	3.20	3.46	3.26	3.64

SD	0.973	0.925	0.936	0.993	0.926

Mean	4.03	3.91	4.03	3.85	3.91

SD	0.770	0.843	0.728	0.906	0.843

U (p)	*1,657.5 (0.003)	*1,401.5 (<0.0001)	*1,587.5(0.001)	*1,616.5(0.002)	2,041.0(0.153)

Cohen’s d	−0.627	−0.802	−0.680	−0.621	−0.305


Reported Adverse event	No of related AEs (no. of patients)	CTCAE-grade (range)

Fever	8 (5)	1–2

Chills	2 (2)	1

Rash	1 (1)	1

Hypotension	1 (1)	2

Reported Adverse event	No of related AEs (no. of patients)	CTCAE-grade (range)

Chills	2 (2)	1

Rash	1 (1)	1

Hypotension	1 (1)	2


	+20% Fat group (N = 14)	−20% Fat group (N = 17)

	Pre	Post	P value	Pre	Post	P value

Height (m)	1.76 ± 0.01	1.76 ± 0.01	—	1.74 ± 0.02	1.74 ± 0.02	—


No.	Gene ID	P-value	Fold difference (sensitive vs resistant)	Fold difference (description)

1	SLC1A4	0.00004	2.695	Sensitive up vs resistant

2	NEK3	0.00006	−2.544	Sensitive down vs resistant

3	GLA	0.00007	2.073	Sensitive up vs resistant

4	AKNA	0.00020	4.043	Sensitive up vs resistant

5	ARHGAP27	0.00035	3.599	Sensitive up vs resistant

6	LY96	0.00045	3.796	Sensitive up vs resistant

7	DLST	0.00070	−2.001	Sensitive down vs resistant

8	MSL3	0.00132	2.237	Sensitive up vs resistant

9	SQRDL	0.00134	3.906	Sensitive up vs resistant

10	NCAPH2	0.00206	2.129	Sensitive up vs resistant

11	PLK1S1	0.00262	−2.035	Sensitive down vs resistant

12	MRI1	0.00284	2.448	Sensitive up vs resistant

13	TARS2	0.00294	−2.083	Sensitive down vs resistant

14	OBFC2A	0.00307	3.756	Sensitive up vs resistant

15	RAB8A	0.00319	2.097	Sensitive up vs resistant

16	ABHD2	0.00363	2.475	Sensitive up vs resistant

17	LMF2	0.00364	2.558	Sensitive up vs resistant

18	C6orf48	0.00367	−2.462	Sensitive down vs resistant

19	TUBA4A	0.00400	2.189	Sensitive up vs resistant

20	HSPA1B	0.00467	−2.335	Sensitive down vs resistant

21	TFEB	0.00471	−2.302	Sensitive down vs resistant

22	RNF170	0.00504	−2.34	Sensitive down vs resistant

23	SOX12	0.00569	−2.281	Sensitive down vs resistant

24	ZNFX1-AS1	0.00604	−2.482	Sensitive down vs resistant

25	C2orf69	0.00622	2.038	Sensitive up vs resistant

26	PTPN18	0.00634	2.635	Sensitive up vs resistant

27	PRKD2	0.00641	3.5	Sensitive up vs resistant

28	KHK	0.00662	2.484	Sensitive up vs resistant

29	PAQR6	0.00710	−3.645	Sensitive down vs resistant

30	HIST1H2BD	0.00763	−4.514	Sensitive down vs resistant

31	CERK	0.00776	2.481	Sensitive up vs resistant

32	UBE2K	0.00806	−2.048	Sensitive down vs resistant

33	LYSMD1	0.00814	−2.379	Sensitive down vs resistant

34	GPSM3	0.00832	5.309	Sensitive up vs resistant

35	MNAT1	0.00906	−2.144	Sensitive down vs resistant

36	WFS1	0.00911	2.397	Sensitive up vs resistant

37	MYH9	0.00923	2.011	Sensitive up vs resistant

38	CYTIP	0.00925	2.855	Sensitive up vs resistant

39	SVIP	0.00928	2.148	Sensitive up vs resistant

40	ARSA	0.00931	3.3	Sensitive up vs resistant

41	SFMBT2	0.00947	2.111	Sensitive up vs resistant

42	POLR3GL	0.00958	−2.251	Sensitive down vs resistant

No.	Gene ID

1	SLC1A4

2	NEK3

3	GLA

4	AKNA

5	ARHGAP27

6	LY96

7	DLST

8	MSL3

9	SQRDL

10	NCAPH2

11	PLK1S1

12	MRI1

13	TARS2

14	OBFC2A

15	RAB8A

16	ABHD2

17	LMF2

18	C6orf48

19	TUBA4A

20	HSPA1B

21	TFEB

22	RNF170

23	SOX12

24	ZNFX1-AS1

25	C2orf69

26	PTPN18

27	PRKD2

28	KHK

29	PAQR6

30	HIST1H2BD

31	CERK

32	UBE2K

33	LYSMD1

34	GPSM3

35	MNAT1

36	WFS1

37	MYH9

38	CYTIP

39	SVIP

40	ARSA

41	SFMBT2

42	POLR3GL

P-value	Fold difference (sensitive vs resistant)	Fold difference (description)

0.00004	2.695	Sensitive up vs resistant

0.00006	−2.544	Sensitive down vs resistant

0.00007	2.073	Sensitive up vs resistant

0.00020	4.043	Sensitive up vs resistant

0.00035	3.599	Sensitive up vs resistant

0.00045	3.796	Sensitive up vs resistant

0.00070	−2.001	Sensitive down vs resistant

0.00132	2.237	Sensitive up vs resistant

0.00134	3.906	Sensitive up vs resistant

0.00206	2.129	Sensitive up vs resistant

0.00262	−2.035	Sensitive down vs resistant

0.00284	2.448	Sensitive up vs resistant

0.00294	−2.083	Sensitive down vs resistant

0.00307	3.756	Sensitive up vs resistant

0.00319	2.097	Sensitive up vs resistant

0.00363	2.475	Sensitive up vs resistant

0.00364	2.558	Sensitive up vs resistant

0.00367	−2.462	Sensitive down vs resistant

0.00400	2.189	Sensitive up vs resistant

0.00467	−2.335	Sensitive down vs resistant

0.00471	−2.302	Sensitive down vs resistant

0.00504	−2.34	Sensitive down vs resistant

0.00569	−2.281	Sensitive down vs resistant

0.00604	−2.482	Sensitive down vs resistant

0.00622	2.038	Sensitive up vs resistant

0.00634	2.635	Sensitive up vs resistant

0.00641	3.5	Sensitive up vs resistant

0.00662	2.484	Sensitive up vs resistant

0.00710	−3.645	Sensitive down vs resistant

0.00763	−4.514	Sensitive down vs resistant

0.00776	2.481	Sensitive up vs resistant

0.00806	−2.048	Sensitive down vs resistant

0.00814	−2.379	Sensitive down vs resistant

0.00832	5.309	Sensitive up vs resistant

0.00906	−2.144	Sensitive down vs resistant

0.00911	2.397	Sensitive up vs resistant

0.00923	2.011	Sensitive up vs resistant

0.00925	2.855	Sensitive up vs resistant

0.00928	2.148	Sensitive up vs resistant

0.00931	3.3	Sensitive up vs resistant

0.00947	2.111	Sensitive up vs resistant

0.00958	−2.251	Sensitive down vs resistant


Sample no.	Number of subjects	RhD	RhCcEe	RHD zygosity*	RHD allele

Micro-plate	IAT	Adsorption/elute

13001-13030	30	–	–	+	Ccee	RHD+/RHD-	RHD1227A

13031-13033	3	–	–	+	CCee	RHD+/RHD-	RHD1227A

13034-13035	2	–	–	+	Ccee	RHD+/RHD+	RHD1227A

13036	1	–	–	+	CCEe	RHD+/RHD-	RHD1227A

13037	1	–	–	+	CcEe	RHD+/RHD-	RHD1227A

13038	1	–	–	+	Ccee	RHD+/RHD-	RHD-CE (2-5)-D

13039	1	–	–	+	Ccee	RHD+/RHD-	RHD-CE (4-7)-D

13040	1	–	–	+	Ccee	RHD+/RHD+	RHD93T>A

13041	1	–	–	+	Ccee	RHD+/RHD-	RHD838G>A

RhD	RhCcEe	RHD zygosity*	RHD allele

Micro-plate	IAT	Adsorption/elute

–	–	+	Ccee	RHD+/RHD-	RHD1227A

–	–	+	CCee	RHD+/RHD-	RHD1227A

–	–	+	Ccee	RHD+/RHD+	RHD1227A

–	–	+	CCEe	RHD+/RHD-	RHD1227A

–	–	+	CcEe	RHD+/RHD-	RHD1227A

–	–	+	Ccee	RHD+/RHD-	RHD-CE (2-5)-D

–	–	+	Ccee	RHD+/RHD-	RHD-CE (4-7)-D

–	–	+	Ccee	RHD+/RHD+	RHD93T>A

–	–	+	Ccee	RHD+/RHD-	RHD838G>A


Trial number andaverage error	User 1	User 2	User 3	User 4	User 5	User 6	User 7	User 8	User 9	User 10

1st trial	0.59	0.46	0.76	0.51	0.82	0.78	0.56	0.84	0.93	0.72


Method	Week 4	Week 5

Positive/total	Specificity (%)	Sensitivity (%)	Positive/total	Specificity (%)	Sensitivity (%)

FIU	18/53	72.3	83.3	12/53	83.3	80

CM	13/53	81	66.6	7/53	91.7	60

FIU+CM	8/53	91.5	66.6	6/53	93.8	60

Method	Positive/total	Specificity (%)	Sensitivity (%)	Positive/total	Specificity (%)	Sensitivity (%)

FIU	18/53	72.3	83.3	12/53	83.3	80

CM	13/53	81	66.6	7/53	91.7	60

FIU+CM	8/53	91.5	66.6	6/53	93.8	60


Incremental # sub-types	P-valuesa

mRNA	Methylation

3 vs 2	0.02	<0.01

4 vs 3	0.06	0.04

5 vs 4	0.41	<0.01

Incremental # sub-types	mRNA	Methylation

3 vs 2	0.02	<0.01

4 vs 3	0.06	0.04

5 vs 4	0.41	<0.01


Variable	All NEETs Included	Economically Inactive NEETs Excluded

OR (95% CI)	OR (95% CI)

UNIVARIATEc

NEET

No	1.00*	1.00

Yes	0.73 (0.59–0.90)	0.90 (0.69–1.19)

FULLY ADJUSTEDc

NEET

No	1.00*	1.00

Yes	0.71 (0.56–0.91)	0.91 (0.68–1.22)

Sex

Male	0.71 (0.60–0.85)	0.69 (0.58–0.82)

Female	1.00**	1.00**

Ethnicity

White UK & Irish	1.00**	1.00**

Other (incl. gypsy/traveller)	0.43 (0.33–0.56)	0.41 (0.31–0.54)

Access to car/van

Yes	1.00*	1.00*

No	1.24 (1.03–1.49)	1.29 (1.06–1.56)

Marital status

Married/cohabiting	0.65 (0.53–0.80)	0.67 (0.54–0.83)

Other (incl. single/separated/divorced)	1.00**	1.00**

Receipt of means-tested benefits

No	1.00*	1.00*

Yes	0.80 (0.67–0.95)	0.80 (0.67–0.96)

NSSEC

Managerial & professional	1.00*	1.00*


Group	Dose (mg/kg)	AST (IU/l)	ALT (IU/l)


Grouping variable	Variance	F-value	P-value

Year	0.73	37.86	<0.001

Farmland type	0.08	4.27	0.001

Year: Farmland type	0.13	6.48	<0.001

Grouping variable	Variance	F-value	P-value

		3	<0.00


Health facility indicators	DRH	HFSUH	KGH	Over all

Percentage in stock of key drugs	12(80.0%)a	6(40.0%)a	11(73.3%)a	20(66.7%)

% of drugs with adequate recording	11(73.3%) a	0a	12(80.0%)a	19(63.3)

Average number of stock out days during the year for adequately recorded drugs	9.78	__	35a	30

Percentage of Expired drug	0	7(46.7%)a	6(40.0%)a	8(26.7%)a


Sociodemographic and clinical variablesa	Patients with TRD (n=12)	Comparison participants (n=10)	Statisticb	P-value

Age, years: mean (s.d.)	59.17 (8.02)	54.4 (8.37)	−1.454	0.159

Gender, male: n (%)	6 (50)	5 (50)	0	1

Education, years: mean (s.d.)	9.75 (5.91)	12.44 (3.39)	−1.253	0.219

Psychotic symptoms: n (%)	5 (41.7)

Comorbid anxiety disorder: n (%)	3 (25)

Age at onset, years: mean (s.d.)	40.58 (19.00)

Duration of current episode, weeks: mean (s.d.)	61.75 (134.46)

Number episodes: mean (s.d.)	4.08 (2.71)

HRSD1c: mean (s.d.)	31.25 (9.21)

HRSD2: mean (s.d.)	28.50 (9.52)

HRSD3: mean (s.d.)	6.75 (5.17)

HRSD4: mean (s.d.)	2.92 (2.54)

MSM: mean (s.d.)	9.33 (1.15)

Drugs: %

 Antidepressant	100

 Antipsychotics	75

 Lithium	16.7

 Anxiolytics	50

Previous ECT: %	16.7


Clinical characteristics	Total

Patient number	269

Gender (female)	204 (75.8)

Age at diagnosis (year)	46.8 ± 15.1

Mean tumor size (cm)	3.0 ± 1.5

Post-operative serum Tg level after 1 month (ng/mL)	96.2 ± 515.5

Multifocality	65 (24.2)

Histology variant

Follicular variant of papillary	10 (3.5)

Poorly differentiation	4 (1.5)

Tall cell	1 (0.4)

Thyroid operative method

Total thyroidectomy	137 (50.9)

Total thyroidectomy with LN dissection	132 (49.1)

Lymph node metastases	80 (29.7)

Non-remission	44 (16.4)

Follow-up period (year)	13.3 ± 5.5

Post-operative 131I accumulative dose (mCi)	209.5 ± 253.2

Cancer mortality	28 (10.4)

Total mortality	63 (23.4)

Disease free	89 (33.1)

Second primary cancer	29 (10.8)

Mortality	15 (51.7)

Diabetes mellitus	21 (7.8)


Variable category	Total

	(N = 175)

Gender	(N = 175)

Male	(104, 59.4%)

Female	(71, 40.6%)

Age (years) (mean ± SD)	(N = 175)

(56.6 ± 9.4)

Clinical diagnosis	(N = 175)

Early gastric cancer	(40, 22.9%)

Dysplasia	(19, 10.9%)

Peptic ulcer disease	(34, 19.4%)

Chronic gastritis	(82, 46.9%)

Histological AG in either antrum or body	(N = 116)

Yes	(67, 57.8%)

No	(49, 42.2%)

Histological IM in either antrum or body	(N = 144)

Yes	(84, 58.3%)

No	(60, 41.7%)


Design theory	Definition	Example

Accessible design [46]	Provides separate design features for user groups with disabilities Usually permanent and noticeableFulfills code requirements for use by individuals with disabilities 	Provide the minimum level of accessibility required by the local building code. This can vary by region (e.g., province or state), and with different building types within the same region. For example, Ontario Building Code requires power door operators (e.g., push button, automatic sensor, etc.) on entrances to hotels, but not on entrances to stand-alone office spaces of less than 300 m2 [47].

Adaptable design [46]	Provides design features that are usable by groups with disabilities, however remain concealed or omitted until neededFeatures are either adjustable or easily and quickly added or removed in order to “adapt” the environment for specific individuals	An electronic push button is provided to open the door, but the use of the push button is optional (i.e., door will open manually).

Transgenerational design [48]	Develops products and environments that are compatible with the natural physical and sensory declines experienced during the aging process	Provide a power assist door, which augments the force applied by the user to fully open the door [49].

Design theory

Accessible design [46]

Adaptable design [46]

Transgenerational design [48]

Definition	Example

Provides separate design features for user groups with disabilities Usually permanent and noticeableFulfills code requirements for use by individuals with disabilities	Provide the minimum level of accessibility required by the local building code. This can vary by region (e.g., province or state), and with different building types within the same region. For example, Ontario Building Code requires power door operators (e.g., push button, automatic sensor, etc.) on entrances to hotels, but not on entrances to stand-alone office spaces of less than 300 m2 [47].

Provides design features that are usable by groups with disabilities, however remain concealed or omitted until neededFeatures are either adjustable or easily and quickly added or removed in order to “adapt” the environment for specific individuals	An electronic push button is provided to open the door, but the use of the push button is optional (i.e., door will open manually).

Develops products and environments that are compatible with the natural physical and sensory declines experienced during the aging process	Provide a power assist door, which augments the force applied by the user to fully open the door [49].


			dissector

			base

Structure quantified (antibody)	OBJ	ssf	(μm × μm)

Neurofibrillar tangles (AT8)	60 ×	1/13	100 × 100

Microglia (Iba1)	60 ×	1/13	70 × 70

Macrophage-like structures (Iba1)	60 ×	1/13	70 × 70

MHCII-positive microglia - frequent (MHCII)	60 ×	1/13	100 × 100

MHCII-positive microglia - sparse (MHCII)	60 ×	1/13	100 × 100

Astrocytes (GFAP)	60 ×	1/13	70 × 70

Neurons (NeuN)	60 ×	1/13	70 × 70


Group	Survivors of intimate partner violence (n =8)	Women who have not experienced violence (n = 5)	General practitioners (n = 3)

Age group	18-25: 3	18-25: 1	18-25: 0

26-50: 4	26-50: 4	26-50: 2

51-74: 1	51-74: 0	51-74: 1

Mean age	36	36.6	50.6

Number of children	None: 3	None: 3	No data

One: 2	One: 0

Two: 3	Two: 2

Employment status	Employed 1	Employed 4	Employed 3

 	Unemployed 6	Unemployed 1

Retired 1

Ethnicity	Danish 3	Danish 5	Danish 3

Other Scandinavian 1

Other ethnicity 4

Group	Survivors of intimate partner violence (n =8)	Women who have not experienced violence (n = 5)

Age group	18-25: 3	18-25: 1

26-50: 4	26-50: 4

51-74: 1	51-74: 0

Mean age	36	36.6

Number of children	None: 3	None: 3

One: 2	One: 0

Two: 3	Two: 2

Employment status	Employed 1	Employed 4

	Unemployed 6	Unemployed 1

Retired 1

Ethnicity	Danish 3	Danish 5

Other Scandinavian 1

Other ethnicity 4

General practitioners (n = 3)

18-25: 0

26-50: 2

51-74: 1

50.6

No data

Employed 3

Danish 3


Patient Characteristic	First Line	Supporting Reference

Elderly	Lamotrigine or Levetiracetam	[26, 27]

Female of reproductive age	Lamotrigine	[25-27]

Pregnant	Lamotrigine	[26, 27]

Liver failure	Levetiracetam or Lamotrigine or Gabapentina	[26, 27]

Renal failure	Lamotrigine or Valproic acidb	[26, 27]

Depression	Lamotrigine or Valproic acidb or Oxcarbazepinec	[26, 27]


Characteristic	Number (n) or Median (Range)

Median age (years)	22.5 (18–26)

Ethnicity (n)

White British	8

Pakistani British	1

Indian British	2

Canadian (various ethnicities)	4

Gender (n)

Female	15

Male	3

Median number of lifetime sexual partners	3.5 (1–8)

Median number of new sexual partners (in last 12 months)	0 (0–4)

Previous self-test use (n)

Had self-tested	11

Had not self-tested	7

Previous self-test location (n)

Home	3

University Students’ Union	5

Clinic	3


Characteristic	Focus groups (N = 5)	Interviews (N = 10)

No. participants	n = 20	n = 10

Mean age (years)	88.4 (SD ± 5.20)	88.9 (SD ± 3.60)

Gender

Male	20 % (n = 4)	-

Female	80 % (n = 16)	100 % (n = 10)

Marital status

Single	5 % (n = 1)	10 % (n = 1)

Widowed	85 % (n=17)	80 % (n = 8)

Married	5 % (n = 1)	-

Separated	-	-

Divorced	5 % (n = 1)	-

Common-law	-	-

Education

Public school	30 % (n = 6)	10 % (n = 1)

High school	45 % (n = 9)	30 % (n = 3)

College (diploma)	10 % (n = 2)	30 % (n = 3)

University (Bachelors)	5 % (n = 1)	10 % (n = 1)

University (Masters)	5 % (n = 1)	-

University (PhD/MD)	-	-

Other education	5 % (n = 1)	20 % (n = 2)

Perceived Healtha

Excellent	5 % (n = 1)	10 % (n = 1)

Very good	20 % (n = 4)	30 % (n = 3)

Good	50 % (n = 10)	40 % (n = 4)

Fair	25 % (n = 5)	20 % (n = 2)

Poor	-	-

Mean Self-Rated Independenceb

Completely independent	10 % (n = 2)	20 % (n = 2)

Very independent	25 % (n = 5)	70 % (n = 7)

Somewhat independent	25 % (n = 5)	10 % (n = 1)

Very little independence	5 % (n = 1)	-

Not at all independent	-	-


Variable

Mean age ± SD

Classification score of disease conditions

1

2

3

4

5

Gender

Male

Female

Community infections

Repeated hospitalization

Low immune function


Element type of membrane	Pressure driving force bar

NF90-4040	6.96 bar

Parameters mg/L	Internal (Feed water) mg/L	Output Permeable (NF Process) mg/L

TDS	3902.78	212.58

Cl ̄1	1223.4	101.31

Na+1	812.41	67.53


	Dependent variables

	HH CI	HH ACI	HH SCI	HH SACI	N

Public expenditure on health care (% of GDP)	0.0036*	0.0108**	0.0004	0.0035	22

Gini index	−0.0003	−0.0015	0.0005	0.0004	26

Public expenditure on education (% of GDP)	−0.0048	−0.0038	−0.0050**	−0.0058	25

GDP PPS per capita (in millions)	0.0770	0.8780	−0.2560	0.0403	26

GDP euros per capita (in millions)	0.0515	0.6600*	−0.1910	0.0438	26

Nordic countries	0.0015	0.0142	−0.0040	0.0010	26

Eastern Europe	0.0045	−0.0143	0.0087*	−0.0002	26

Southern Europe	−0.0036	−0.0037	0.0001	0.0024	26

North-Western Europe	−0.0028	0.0076	−0.0064	−0.0027	26

	Dependent variable


Gene symbol	Description	Gene function	Gene expression in IBS	Psychiatric diseases	Reference

NGF	Nerve growth factor	Pro-inflammatory mediator; psychoneuroendocrine modulator	Overexpression (in rat model)	Anxiety, chronic alcohol consumption, depression	[71, 72]

BDNF	Brain-Derived Neurotrophic Factor	Regulation of stress response and in the biology of mood disorders	SNP	Psychiatric IBS, schizophrenia, mood disorders, PTSD	[73, 74]

COMT	Catechol	Degradative pathways of the catecholamine transmitters; metabolism of catechol drugs	SNP	Anxiety, panic disorder, and cognitive performance	[75, 76]

O-Methyltransferase

OPRM1	Mu Opiate Receptor	Principal target of endogenous opioid peptides	SNP	Pain sensitivity, opioid dependence, and social sensitivity	[77, 78]

5-HTTLPR	5-hydroxytryptamine transporter gene-linked polymorphic region	Serotonin transporter	SNP	Depression, anxiety, rectal pain ratings	[79, 80]

Gene symbol	Description	Gene function	Gene expression in IBS	Psychiatric diseases	Reference

5-HTTLPR	5-hydroxytryptamine transporter gene-linked polymorphic region	Serotonin transporter	SNP	Depression, anxiety, rectal pain ratings	[79, 80]


Recombinant strain	Transfer medium	Resistant colonies (%)

RQ7/pDH10	SVO	104.92 ± 9.57

	SVO + Kan	106.66 ± 3.56

Tm/pDH10	SVO	100.96 ± 23.72

	SVO + Kan	108.59 ± 7.54

Recombinant strain	Transfer medium	Resistant colonies (%)

Tm/pDH10	SVO	100.96 ± 23.72

	SVO + Kan	108.59 ± 7.54


Lower than high school	27 (64.29)	44 (65.67)

High school and above	15 (35.71)	23 (34.33)


Nucleotide (genomic)	Nucleotide (cDNA)	Amino Acid	Type	Age at Onset	Number of affected	TCGA_ID	Previous Reported

11:108098418C>T	c.G67T	p.R23X	Nonsense	71	1	TCGA-RD-A8MV*	NA

11:108106511delTTCT	c.446_449del	p.I149fs	Frameshift deletion	46	1	TCGA-BR-6564	NA

11:108121753delAG	c.1561_1562del	p.R521fs	Frameshift deletion	NA	1	TCGA-HF-7133	NA

11:108183151G>T	c.G5932T	p.E1978X	Nonsense	41,64	2	TCGA-BR-6710TCGA-BR-8077	Li and Swift et al., 2000

11:108214065delTTTCAGTGCC	c.8385_8395del	p.D2795fs	Frameshift deletion	57	1	TCGA-VQ-AA6F	NA

11:108216616T>G	c.8565T>G	p.S2855R	Missense	64	1	TCGA-BR-7196	Castellvi-Bel et al., 1999

11:108186638G>A	c.6095G>A	p.R2032K	Missense	70	1	TCGA-BR-8365	Li and Swift et al., 2000

11:108199929T>G	c.7271T>G	p.V2424G	Missense	71	1	TCGA-RD-A7BW	Stankovic et al., 1998

Nucleotide (genomic)	Nucleotide (cDNA)	Amino Acid	Type	Age at Onset	Number of affected	TCGA_ID	Previous Reported

11:108183151G>T	c.G5932T	p.E1978X	Nonsense	41,64	2	TCGA-BR-6710TCGA-BR-8077	Li and Swift et al., 2000

11:108214065delTTTCAGTGCC	c.8385_8395del	p.D2795fs	Frameshift deletion	57	1	TCGA-VQ-AA6F	NA

11:108216616T>G	c.8565T>G	p.S2855R	Missense	64	1	TCGA-BR-7196	Castellvi-Bel et al., 1999

11:108186638G>A	c.6095G>A	p.R2032K	Missense	70	1	TCGA-BR-8365	Li and Swift et al., 2000

11:108199929T>G	c.7271T>G	p.V2424G	Missense	71	1	TCGA-RD-A7BW	Stankovic et al., 1998


Component	Low-N Plot	Net Change (g N m–2)	High-N Plot	Net Change (g N m−2)

Before	After	Before	After

N input–output (g N m−2 year−1)

N input	0	5	5	0	15	15

N leaching	0.66	0.77	0.11	0.42	2.67	2.25

N retention			4.89			12.75

N storage (g N m−2)

Aboveground biomass N	15.68	9.26	−6.42	13.36	19.12	5.76

Belowground biomass N	4.59	7.29	2.71	5.54	8.12	2.58

N mass remaining in litter	0.85	1.18	0.33	1.37	1.73	0.36

Soil inorganic N	4.10	3.92	−0.18	3.50	3.94	0.44

Estimated N storage			8.11			2.72

Component	Low-N Plot	Net Change (g N m–2)	High-N Plot

Before	After	Before

N input–output (g N m−2 year−1)

N input	0	5	5	0

N leaching	0.66	0.77	0.11	0.42

N retention			4.89

N storage (g N m−2)

Aboveground biomass N	15.68	9.26	−6.42	13.36

Belowground biomass N	4.59	7.29	2.71	5.54

N mass remaining in litter	0.85	1.18	0.33	1.37

Soil inorganic N	4.10	3.92	−0.18	3.50

Estimated N storage			8.11


	M5:M5	M5:G1F	M5:M3G1F	M5:G0F	M5:M3G0F	G0F:G0F

Calculated relative	0.62%	1.12%	0.11%	5.29%	0.18%	45.43%

Calculated relative to the most abundant G0F:G0F	1.36%	2.46%	0.24%	11.64%	0.40%	100%

Observed relative to the most abundant G0F:G0F	5.13%	ND	ND	12.73%	ND	100%


Variable	Normal BMD group (N = 17)

Trunk

Tilt ROM	4.05 ± 1.31

Rotation ROM	16.06 ± 4.46

Obliquity ROM	9.49 ± 2.59

Hip

Sagittal ROM	41.24 ± 7.36

Coronal ROM	11.50 ± 3.68

Transverse ROM	14.28 ± 2.36


Socio-demographic characteristics

Mean age (range) years	21 (17 – 30)

Occupation (n)

 Farmer	3

 Factory worker	2

 Student	1

Education level (n)

 Completed secondary school	5

 Vocational high school training	1

Marital status (n)

 Married	6

Perception of economic status (n)

 Similar to other households in this area	6

Parity (n)

 Nulliparous	4

 Multiparous	2

Number of household members over prior six months, median (range)	5 (4 – 6)

Persons participant living with in the same household (n)

 Husband	6

 Mother-in-law	6

 Father-in-law	6

 Husband’s brother/sister	2

 Husband’s grandmother	1

 Mother	2

Reproductive health

 Median gestation (range) weeks	32.5 (28 – 35)

Current pregnancy (n)

 Very welcome	6

Coincidental adverse events

 No current worrying or distressing coincidental life events	6

Relationship with partner

Ever experienced fear of husband over the past year (n)

 Never	4

 Sometimes or often	2

Ever physically hurt by husband over last year (n)

 Never	6


Sociodemographic characteristics	Health-related characteristics

Males N (%)	119 (41.8)	Smokers N (%)	81 (28.4)

Mean Age in years (SD)	50.18 (10.1)	Mean Pack-years for smokers (SD)	24.82 (21.8)

Married N (%)	188 (66)	Mean BMI in Kg/m2 (SD)	26.34 (5.34)

Living alone N (%)	55 (19.3)	Diagnosis of Disease N (%)	130 (45.6)

Having children N (%)	209 (73.3)	Mean PSS score (SD)	26.35 (7.99)

Tertiary education N (%)	165 (57.9)	Mean Internal HLC score (SD)	26.12 (4.96)

Employed N (%)	214 (75.1)	Mean External HLC score (SD)	22.23 (6.04)

Working shifts N (%)	64 (22.5)	Mean Chance HLC score (SD)	16.75 (6.04)

Caregivers N (%)	22 (7.7)	SRRS score N (%)

≤150	164 (57.5)

151-299	80 (28.1)

≥300	41 (14.4)

	Mean Sleep Quality (SD)	6.16 (2.13)

Mean Health Assessment (in a scale from 1 to 10) (SD)	7.48 (1.4)


		GGT	Vitamin C

	Sample (n)	β-Coefficient	p-Value for trend	β-Coefficient	p-Value for trend

25–29.9	3,567	0.045	< 0.01	−0.090	< 0.01

≥30	2,631	0.032	0.02	−0.107	< 0.01

p-Value for interaction		< 0.01		< 0.01


marker	# of markers	detectable strains	data quality

Minimal set of SNPs	2	known	perfect

All SNPs + VNTRs	150+15	some unknown	moderate

CDSs	~10,000	many unknown	poor

Sequence alignment	~5,300,000	arbitrary	arbitrary

marker	# of markers

Minimal set of SNPs	2

All SNPs + VNTRs	150+15

CDSs	~10,000

Sequence alignment	~5,300,000

detectable strains	data quality

known	perfect

some unknown	moderate

many unknown	poor

arbitrary	arbitrary


Factor	Patients no	P Value

CR	PR

Sex			0.889

Male	45 (64.2%)	7 (10.2%)

Female	15 (21.4%)	3 (4.2%)

Pathological subtype			0.133

Non keratinizing	9 (12.9%)	4 (5.7%)

Undifferentiated	45 (64.3%)	5 (7.1%)

Basaloid	5 (7.1%)	2 (2.9 %)


		ELISA	PCR

		B. bigemina	B. bovis	B. bigemina and B. bovis	B. bigemina	B. bovis

Governorate	No. tested animals	No. of positive animals	Infection (%)	No. of positive animals	Infection (%)	No. of positive animals	Co-infection (%)	No. of positive animals	Infection (%)	No. of infected animals	Infection (%)

Kafr El-Sheikh	7	5	71.4	3	42.9	2	28.6	0	0	2	28.6

El-Beheira	74	13	17.6	15	20.3	3	4.1	0	0	1	1.4

Total	81	18	22.2	18	22.2	5	6.2	0	0	3	3.7

		ELISA	PCR

		B. bigemina	B. bovis	B. bigemina and B. bovis	B. bigemina	B. bovis

Governorate	No. tested animals	No. of positive animals	Infection (%)	No. of positive animals	Infection (%)	No. of positive animals	Co-infection (%)	No. of positive animals	Infection (%)	No. of infected animals

Kafr El-Sheikh	7	5	71.4	3	42.9	2	28.6	0	0	2

El-Beheira	74	13	17.6	15	20.3	3	4.1	0	0	1

Total	81	18	22.2	18	22.2	5	6.2	0	0	3

PCR

B. bovis

Infection (%)

28.6

1.4

3.7


Author	Aims scope	Ethical dimension	Study design	Rigour	Analysis procedure	Depth/detail	Credibility	Relevance transferability	Contribution to knowledge	Overall quality

Andersen et al. (a) and (b)	VG	VG	VG	G	VG	G	VG	VG	VG	VG

Apps et al.	VG	VG	VG	VG	VG	VG	G	VG	VG	VG

Boeckxstaens et al.	VG	VG	VG	VG	VG	G	VG	VG	VG	VG

Brandt	G	VG	VG	VG	VG	L	L	G	G	G

Brien et al.	VG	VG	G	G	G	G	G	G	G	G

Chang et al.	VG	G	G	G	VG	G	G	G	G	G

Chen et al. (a) and (b)	VG	VG	G	VG	VG	VG	L	VG	VG	VG

Cicutto et al.	VG	VG	VG	VG	VG	VG	VG	VG	VG	VG

Duangpaeng et al.	VG	G	G	G	G	G	L	G	G	G

Ehrlich et al.	VG	VG	VG	VG	VG	VG	G	VG	VG	VG

Fotokain et al.	G	VG	G	VG	VG	G	G	G	G	G

Gysels and Higginson	VG	VG	VG	VG	VG	VG	VG	VG	VG	VG

Harris et al.	VG	G	VG	VG	VG	VG	VG	VG	VG	VG

Harrison et al.	VG	VG	VG	VG	VG	VG	VG	VG	VG	VG

Hillebregt et al.	G	VG	VG	VG	VG	G	G	VG	VG	VG

Hyde et al.	VG	G	VG	VG	VG	VG	G	VG	VG	VG

Johnston et al. (a)	VG	VG	VG	VG	VG	G	G	VG	VG	VG

Johnston et al. (b)	VG	G	VG	VG	G	VG	VG	VG	VG	VG

Kayyali et al.	VG	G	G	G	G	G	L	G	G	G

McCabe et al.	VG	G	VG	G	G	G	G	VG	VG	G

Ogunbayo et al.	VG	VG	G	VG	VG	G	VG	VG	VG	VG

Panos et al.	VG	G	VG	VG	VG	VG	G	VG	VG	VG

Robinson et al.	VG	VG	G	VG	VG	G	VG	VG	VG	VG

Sheridan et al.	VG	VG	VG	G	L	VG	VG	VG	VG	VG

Stellefson et al.	VG	VG	VG	VG	VG	VG	VG	G	G	VG

Summers et al.	VG	VG	G	VG	VG	G	VG	VG	VG	VG

Verbrugge et al.	VG	G	VG	VG	VG	VG	VG	VG	VG	VG

Wong et al.	VG	VG	VG	G	G	VG	G	VG	VG	VG

Wortz et al.	VG	VG	G	G	G	VG	VG	VG	VG	VG

Young et al.	VG	VG	VG	G	G	VG	G	VG	VG	VG

Zakrisson and Hagglund	VG	G	G	G	G	VG	G	VG	VG	G

Author	Aims scope	Ethical dimension	Study design	Rigour	Analysis procedure	Depth/detail	Credibility	Relevance transferability	Contribution to knowledge	Overall quality

Andersen et al. (a) and (b)	VG	VG	VG	G	VG	G	VG	VG	VG	VG

Apps et al.	VG	VG	VG	VG	VG	VG	G	VG	VG	VG

Boeckxstaens et al.	VG	VG	VG	VG	VG	G	VG	VG	VG	VG

Brandt	G	VG	VG	VG	VG	L	L	G	G	G

Brien et al.	VG	VG	G	G	G	G	G	G	G	G

Chang et al.	VG	G	G	G	VG	G	G	G	G	G

Chen et al. (a) and (b)	VG	VG	G	VG	VG	VG	L	VG	VG	VG

Cicutto et al.	VG	VG	VG	VG	VG	VG	VG	VG	VG	VG

Duangpaeng e	V		G		G	G	L		G

Author	Aims scope	Ethical dimension	Study design	Rigour	Analysis procedure	Depth/detail	Credibility	Relevance transferability	Contribution to knowledge	Overall quality

t al.	G	G		G				G		G

Ehrlich et al.	VG	VG	VG	VG	VG	VG	G	VG	VG	VG

Fotokain et al.	G	VG	G	VG	VG	G	G	G	G	G

Gysels and Higginson	VG	VG	VG	VG	VG	VG	VG	VG	VG	VG

Harris et al.	VG	G	VG	VG	VG	VG	VG	VG	VG	VG

Harrison et al.	VG	VG	VG	VG	VG	VG	VG	VG	VG	VG

Hillebregt et al.	G	VG	VG	VG	VG	G	G	VG	VG	VG

Hyde et al.	VG	G	VG	VG	VG	VG	G	VG	VG	VG

Johnston et al. (a)	VG	VG	VG	VG	VG	G	G	VG	VG	VG

Johnston et al. (b)	VG	G	VG	VG	G	VG	VG	VG	VG	VG

Kayyali et al.	VG	G	G	G	G	G	L	G	G	G

McCabe et al.	VG	G	VG	G	G	G	G	VG	VG	G

Ogunbayo et al.	VG	VG	G	VG	VG	G	VG	VG	VG	VG

Panos et al.	VG	G	VG	VG	VG	VG	G	VG	VG	VG

Robinson et al.	VG	VG	G	VG	VG	G	VG	VG	VG	VG

Sheridan et al.	VG	VG	VG	G	L	VG	VG	VG	VG	VG

Stellefson et al.	VG	VG	VG	VG	VG	VG	VG	G	G	VG

Summers et al.	VG	VG	G	VG	VG	G	VG	VG	VG	VG

Verbrugge et al.	VG	G	VG	VG	VG	VG	VG	VG	VG	VG

Wong et al.	VG	VG	VG	G	G	VG	G	VG	VG	VG

Wortz et al.	VG	VG	G	G	G	VG	VG	VG	VG	VG

Young et al.	VG	VG	VG	G	G	VG	G	VG	VG	VG

Zakrisson and Hagglund	VG	G	G	G	G	VG	G	VG	VG	G


Sample	Peel	Pulp

K. pneumoniae	Activity	S. aureus	Activity	K. pneumoniae	Activity	S. aureus	Activity

Jeruk Nipis	4.2 ± 1.8a	Bactericide	3.5 ±1.4a,b	Bacteriostatic	4.1 ± 0.4a,b	Bactericide	3.1 ± 0.6a,b	Bactericide

Jeruk Purut	4.6 ± 1.2a	Bacteriostatic	4.8 ± 1.7a,b	Bactericide	5.5 ± 1.1a,b	Bactericide	3.4 ± 0.9a,b	Bactericide

Calung	5.6 ± 0.7a	Bacteriostatic	7.0 ± 1.9b	Bacteriostatic	7.5 ± 1.1b	Bactericide	6.2 ± 2.0b	Bacteriostatic

Makin	4.1 ± 0.9a	Bacteriostatic	2.5 ± 0.5a	Bactericide	3.3 ± 0.3a 	Bactericide	2.6 ± 0.6a	Bactericide

Kruet Mameh	4.3 ± 0.9a	Bactericide	4.1 ± 1.0a,b	Bactericide	6.8 ± 2.5a,b	Bacteriostatic	4.7 ± 1.5a,b	Bacteriostatic

Mentui	11.6 ± 3.5b	Bacteriostatic	4.8 ± 1.8a,b	Bacteriostatic	6.3 ± 1.0a,b	Bacteriostatic	4.1 ± 0.5a,b	Bacteriostatic

Sample	Peel	Pulp

K. pneumoniae	Activity	S. aureus	Activity	K. pneumoniae	Activity	S. aureus	Activity

Jeruk N		Bacte	3.5 ±1.		4.1 ± 0	Bacterici	3.1 ± 0.6	Bac

ipis	4.2 ± 1.8a	ricide	4a,b	Bacteriostatic	.4a,b	de	a,b	tericide

Jeruk Purut	4.6 ± 1.2a	Bacteriostatic	4.8 ± 1.7a,b	Bactericide	5.5 ± 1.1a,b	Bactericide	3.4 ± 0.9a,b	Bactericide

Calung	5.6 ± 0.7a	Bacteriostatic	7.0 ± 1.9b	Bacteriostatic	7.5 ± 1.1b	Bactericide	6.2 ± 2.0b	Bacteriostatic

Makin	4.1 ± 0.9a	Bacteriostatic	2.5 ± 0.5a	Bactericide	3.3 ± 0.3a	Bactericide	2.6 ± 0.6a	Bactericide

Kruet Mameh	4.3 ± 0.9a	Bactericide	4.1 ± 1.0a,b	Bactericide	6.8 ± 2.5a,b	Bacteriostatic	4.7 ± 1.5a,b	Bacteriostatic

Mentui	11.6 ± 3.5b	Bacteriostatic	4.8 ± 1.8a,b	Bacteriostatic	6.3 ± 1.0a,b	Bacteriostatic	4.1 ± 0.5a,b	Bacteriostatic


Gene symbol	Gene title	log2 fold change	P-value

VTRNA1-2	vault RNA 1-2	2.28	0.026

PGF	Placenta growth factor	0.70	0.013

RNH1	ribonuclease/angiogenin inhibitor 1	0.57	0.036

ITPK1	inositol 1,3,4-triphosphate 5/6 kinase	0.55	0.037

Mir-503	microRNA 503	0.52	0.047

RAD23A	RAD23 homolog A (S. cerevisiae)	0.52	0.013

APOC1	apolipoprotein C-I	0.50	0.037

USP15	ubiquitin specific peptidase 15	−0.87	0.026

PPP1R12A	protein phosphatase 1. regulatory (inhibitor) subunit 12A	−0.88	0.021

FNBP1L	formin binding protein 1-like	−0.89	0.046

SMC6	structural maintenance of chromosomes 6	−0.92	0.026

SMC4	structural maintenance of chromosomes 4	−0.92	0.024

ROCK2	Rho-associated. coiled-coil containing protein kinase 2	−0.92	0.021

AKAP9	A kinase (PRKA) anchor protein (yotiao) 9	−0.94	0.028

COPS2	COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis)	−0.98	0.008

GCC2	GRIP and coiled-coil domain containing 2	−1.02	0.019

ROCK1	Rho-associated. coiled-coil containing protein kinase 1	−1.07	0.028

Gene symbol	Gene title	log2 fold change	P-value

VTRNA1-2	vault RNA 1-2	2.28	0.026

PGF	Placenta growth factor	0.70	0.013

RNH1	ribonuclease/angiogenin inhibitor 1	0.57	0.036

ITPK1	inositol 1,3,4-triphosphate 5/6 kinase	0.55	0.037

Mir-503	microRNA 503	0.52	0.047

RAD23A	RAD23 homolog A (S. cerevisiae)	0.52	0.013

APOC1	apolipoprotein C-I	0.50	0.037

USP15	ubiquitin specific peptidase 15	−0.87	0.026

PPP1R	protein phosphatase 1. regulatory (inh	−0	0.

12A	ibitor) subunit 12A	.88	021

FNBP1L	formin binding protein 1-like	−0.89	0.046

SMC6	structural maintenance of chromosomes 6	−0.92	0.026

SMC4	structural maintenance of chromosomes 4	−0.92	0.024

ROCK2	Rho-associated. coiled-coil containing protein kinase 2	−0.92	0.021

AKAP9	A kinase (PRKA) anchor protein (yotiao) 9	−0.94	0.028

COPS2	COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis)	−0.98	0.008

GCC2	GRIP and coiled-coil domain containing 2	−1.02	0.019

ROCK1	Rho-associated. coiled-coil containing protein kinase 1	−1.07	0.028


Assembly	Dz (nm)	ζ (mV)	P	References

DODAB BF	59 ± 1	43 ± 2	0.215 ± 0.006	[24]


 	Study sample	 	All first-time fathers in Norway*

 	n	%	n	%	p-value**

Age groups	 	 	 	 	<0.001

25-34 years	11 363	76.6	163 063	77.0

35-39 years	2 693	18.2	34 291	16.2

≥40 years	776	5.2	14 408	6.8

Mother tongue other than Norwegian	1 016	6.9	46 293	21.9	<0.001

Education	 	 	 	 	<0.001

Primary school	288	2.0	29 511	13.9

Secondary school	4 862	33.7	87 850	41.5

Higher education ≤4 years	4 301	29.8	53 193	25.1

Higher education >4 years	4 984	34.5	27 635	13.1

Unknown	397	2.7	13 573	6.4


				p-value+

	CONV	UTR	UCR	Overall

N participants with dry weight reduction	12	17	14

DBP-pre: BCM Measurement [mmHg]	74 ± 15	67 ± 13	76 ± 20	0.23

DBP-pre: Start Intervention Phase [mmHg]	73 ± 14	70 ± 15	85 ± 26	0.09

DBP-post: Start Intervention Phase [mmHg]	70 ± 13	66 ± 13	75 ± 14	0.17

DBP-pre: End Intervention Phase [mmHg]	66 ± 11	64 ± 11	76 ± 13	0.02

DBP-post: End Intervention Phase [mmHg]	57 ± 15	63 ± 12	69 ± 14	0.10

Delta DBP-pre: Start-to-End In Ph. [mmHg]	−7 ± 11	−5 ± 12	−8 ± 31	0.10

Delta DBP-post: Start-to-End In Ph. [mmHg]	−12 ± 14	−3 ± 9	−6 ± 14	0.14


	1-factor solution*	2-factor solution*	3-factor solution*

	loading	(residual variance)	loading	(residual variance)	loading	(residual variance)

	1		1	2		1	2	3

Items


Health Care Organisation Chart

Processes Maps

Procedures for risk classification and reduction

Procedures and Formal Documents (i.e. budgeting, meeting minutes, etc.)

Documents of Reform Projects

Periodic Education Plan

Clinical Care Pathways

Clinical Records

Operating Theatres Registries

Performance Measurement or Appraisal Tools and Procedures

Health Care Professionals Evaluation Forms

HTA Tools and Procedures

Procedures for Privacy Management

Brochures and Booklets for Patients

Customer Satisfaction Questionnaires


Power Level	TXCTRL Register	Output Power	Current Consumption

31	0xA0FF	0 dBm	17.4 mA

27	0xA0FB	−1 dBm	16.5 mA

23	0xA0F7	−3 dBm	15.2 mA

19	0xA0F3	−5 dBm	13.9 mA

15	0xA0EF	−7 dBm	12.5 mA

11	0xA0EB	−10 dBm	11.2 mA

7	0xA0E7	−15 dBm	9.9 mA

3	0xA0E3	−25 dBm	8.5 mA

Power Level	TXCTRL Register	Output Power	Current Consumption

15	0xA0EF	−7 dBm	12.5 mA

11	0xA0EB	−10 dBm	11.2 mA

7	0xA0E7	−15 dBm	9.9 mA

3	0xA0E3	−25 dBm	8.5 mA


	Weeks of training (n)	Sessions/week (n)	MCT/session (min)	MCT/week (min)

ES	3	2	6	36

6	3	6	108

Total MCT	144

LP	3	2	2	12

6	3	2	36

Total MCT	48

	Weeks of training (n)	Sessions/week (n)	MCT/session (min)	MCT/week (min)

ES	6	3	Total MCT	144

LP	3	2	2	12

6	3	2	36

Total MCT	48


Algorithm	Average CPU Estimation Time (ms)

ML-RL-DR	631.9

ML-RL-SDR	235.6

MM-RL-DR	368.8

MM-RL-SDR	243.9

WLS	6.8

ML-JE-Wang	245.0

MM-JE-Wang	295.9

Algorithm	Average CPU Estimation Time (ms)

ML-JE-Wang	245.0

MM-JE-Wang	295.9


Species (Classification) No. of genomes analyzed	Genome size (mb)	Habitat niche	Disease	References

Neisseria meningitidis (Betaproteobacteria) 5	2.2	Upper airway colonizer	Meningitis, septicemia, Waterhouse–Friderichsen syndrome	Parkhill et al. (2000a), Tettelin et al. (2000)

Neisseria gonorrhoeae (Betaproteobacteria) 1	2.1	Urethra	Gonorrhea	Oklahoma University Website

Haemophilus influenzae (Gammaproteobacteria) 6	1.9	Upper airway colonizer	Pneumonia, meningitis, bacteremia, otitis media and more	Fleischmann et al. (1995)

Streptococcus pneumoniae (Bacilli) 3	2.0	Upper airway colonizer	Pneumonia, septicemia, otitis media, peritonitis, pericarditis, meningitis, brain abscess and more	Tettelin et al. (2001)

Helicobacter pylori (Epsilonproteobacteria) 3	1.6	Stomach and duodenum	Peptic ulcer and gastric cancer	Alm et al. (1999)

Campylobacter jejuni (Epsilonproteobacteria) 6	1.6	Gastrointestinal	Main cause of diarrhea in Europe, inducer of the Guillain Barre syndrome	Parkhill et al. (2000b)

Staphylococcus aureus/MRSA (Bacilli) 14	2.8+	Nose and skin	Pneumonia, meningitis, toxic shock syndrome, septicemia and skin infections	Herron-Olson et al. (2007)

Streptococcus pyogenes (Bacilli) 14	1.9	Throat and skin	Diverse pathogenic outcomes/diseases – flesh-eating bacteria	Ferretti et al. (2001)

M. tuberculosis (Actinobacteria) 5	4.2+	Lungs, extrapulmonary locations	Tuberculosis	Cole et al. (1998)

Bacillus subtilis (Bacilli) 1	4.2	Soil	Reference bacterium	Kunst et al. (1997)

Escherichia coli (Gammaproteobacteria) 18	4.6+	Intestine, sewer	Reference bacterium	Blattner et al. (1997)


Session	Module/Topic	Content example

1. Baseline	Blood Pressure and Hypertension Definitions	"Hypertension" is the medical term for high blood pressure. A person with high blood pressure is sometimes described as "hypertensive."

Essential vs. Secondary Hypertension	Normal blood pressure is a systolic pressure of 120 or less. "Systolic" is the top number in a blood pressure reading.

Systolic and Diastolic Normal Readings

2. Seven Day	Hypertension Risk Factors	High blood pressure has many risk factors. Some you can't control. Family history - High blood pressure tends to run in families.

Other risk factors for high blood pressure are within your control: Too much sodium (salt) in your diet which can cause your body to retain fluid, which increases blood pressure.

3. Thirty Day	Tobacco and Alcohol Use	If you drink more than moderate amounts of it, alcohol can actually raise blood pressure by several points. It can also reduce the effectiveness of high blood pressure medications.

Caffeine Use

Cut back on caffeine. The role caffeine plays in blood pressure is still debatable. Drinking caffeinated beverages can temporarily cause a spike in your blood pressure, but it's unclear whether the effect is temporary or long lasting.

4. Ninety Day	BP Complications	Hypertension is frequently called the "silent killer" because it rarely causes symptoms. This is dangerous because untreated hypertension can lead to strokes, heart attacks, kidney disease, and vision loss.

Complications of Uncontrolled Blood Pressure

Very high blood pressure is dangerous. You should call your Healthcare Provider anytime day or night, if your resting systolic blood pressure is over 180 or your resting diastolic blood pressure is over 110.

Session	Module/Topic	Content example

3. Thirty Day	Tobacco and Alcohol Use	If you drink more than moderate amounts of it, alcohol can actually raise blood pressure by several points. It can also reduce the effectiveness of high blood pressure medications.

Caffeine Use

Cut back on caffeine. The role caffeine plays in blood pressure is still debatable. Drinking caffeinated beverages can temporarily cause a spike in your blood pressure, but it's unclear whether the effect is temporary or long lasting.

4. Ninety Day	BP Complications	Hypertension is frequently called the "silent killer" because it rarely causes symptoms. This is dangerous because untreated hypertension can lead to strokes, heart attacks, kidney disease, and vision loss.

Complications of Uncontrolled Blood Pressure

Very high blood pressure is dangerous. You should call your Healthcare Provider anytime day or night, if your resting systolic blood pressure is over 180 or your resting diastolic blood pressure is over 110.


Type of allergy	No. of studies	Overall accuracy (%)	Application	ANN	SVM	BN	FL

Asthma	18	82.44 ± 23.71	To classify exacerbations [10–14]	1	1	2	1

To classify severity [6, 15, 16]	–	–	1	2

To classify pathologic vs control [4, 17–19]	2	1	–	1

To classify asthma control level [8, 20]	1	–	–	1

To classify how manage their pathology [21]	1	–	–	–

To predict the clinical effect of salbutamol [22, 23]	2	–	–	–

To classify health state[24]	–	–	1	–

ADR	6	94.5 ± 2.12	To predict the posterior probability of a drug (BARDI tool) [28–30]	–	–	3	–

To predict hypersensitivity reaction (AERS database) [25–27]	–	–	3	–

Allergic rhinitis	1	88.31	To classify pathologic vs control [31]	1	–	–	–

Allergic conjunctivitis	1	100	To classify pathologic vs control [32]	1	–	–	–

Atopic dermatitis	1	96.4	To classify pathologic vs control [33]	1	–	–	–

Type of allergy	No. of studies	Overall accuracy (%)	Application	ANN	SVM	BN	FL

Asthma	18	82.44 ± 23.71	To classify how manage their pathology [21]	1	–	–	–

To predict the clinical effect of salbutamol [22, 23]	2	–	–	–

To classify health state[24]	–	–	1	–

ADR	6	94.5 ± 2.12	To predict the posterior probability of a drug (BARDI tool) [28–30]	–	–	3	–

To predict hypersensitivity reaction (AERS database) [25–27]	–	–	3	–

Allergic rhinitis	1	88.31	To classify pathologic vs control [31]	1	–	–	–

Allergic conjunctivitis	1	100	To classify pathologic vs control [32]	1	–	–	–

Atopic dermatitis	1	96.4	To classify pathologic vs control [33]	1	–	–	–


 	Immediately pre coronary angiography	6 months after coronary angiogrpahy	P

Global EF (%)	43 ± 10	44 ± 8	p = NS

The size of infarct area (%)	32 ± 10	30 ± 10	p = NS

Infarct wall movement velocity (cm/s)	1.76 ± 0.76	1.80 ± 0.76	p = NS

End-diastolic volume (LVEDV) (ml)	132 ± 35	136 ± 48	p = NS

End-systolic volume (LVESV) (ml)	75 ± 29	76 ± 29	p = NS

Stroke volume index (SVI) (ml/m2)	29 ± 11	33 ± 15	p = NS

BNP (pg/ml)	155 ± 71	141 ± 69	p = NS

NYHA classification	II-III	II-III	p = NS

	Immediately pre coronary angiography	6 months after coronary angiogrpahy	P

	43 	44 ±	p =

Global EF (%)	± 10	 8	 NS

The size of infarct area (%)	32 ± 10	30 ± 10	p = NS

Infarct wall movement velocity (cm/s)	1.76 ± 0.76	1.80 ± 0.76	p = NS

End-diastolic volume (LVEDV) (ml)	132 ± 35	136 ± 48	p = NS

End-systolic volume (LVESV) (ml)	75 ± 29	76 ± 29	p = NS

Stroke volume index (SVI) (ml/m2)	29 ± 11	33 ± 15	p = NS

BNP (pg/ml)	155 ± 71	141 ± 69	p = NS

NYHA classification	II-III	II-III	p = NS


Rotated Component Matrix(a)

	Verbal Learning & Memory	Processing Speed	Attention and Working Memory	Verbal Fluency and Naming	Concept Formation

Alpha	0.883	0.731	0.555	0.457	0.179

Word List Trial 1	0.592

Word List Trial 2	0.767

Word Recognition	0.774

Word List Trial 3	0.792

Word List Cued Recall (Total)	0.829

Word List Delayed Free Recall	0.834

Choice RT Score Decile		0.559

Simple RT Right Score Decile		0.865

Simple RT Left Score Decile		0.893

DATE Score			0.373

Digit Span Backward (Span)			0.784

Digit Span Forward (Span)			0.804

President/VP Naming				0.799

F Words (30 Seconds)				0.504

Animal Naming (30 seconds)				0.456

Serial 7's				0.496

4 Word Naming					0.745

Similarities					0.732

Rotated Component Matrix(a)

	Verbal Learning & Memory	Processing Speed	Attention and Working Memory	Verbal Fluency and Naming	Concept Formation

Alpha	0.883	0.731	0.555	0.457	0.179

Word List Trial 1	0.592

	0.7

Word List Trial 2	67

Word Recognition	0.774

Word List Trial 3	0.792

Word List Cued Recall (Total)	0.829

Word List Delayed Free Recall	0.834

Choice RT Score Decile		0.559

Simple RT Right Score Decile		0.865

Simple RT Left Score Decile		0.893

DATE Score			0.373

Digit Span Backward (Span)			0.784

Digit Span Forward (Span)			0.804

President/VP Naming				0.799

F Words (30 Seconds)				0.504

Animal Naming (30 seconds)				0.456

Serial 7's				0.496

4 Word Naming					0.745

Similarities					0.732


Predictor	B	SE B	β	R2

Step 1				.05***

SES	.14	.03	.14***

City	.15	.04	.13***

5th grade	.08	.04	.08*

6th grade	.11	.04	.11***

Step 2				.08***

Gender	-.07	.03	-.08*

Ethnic status	-.15	.03	-.16***

Step 3a				.08*

Gender * ethnic status	-.60	.30	-.12*

Mediator: School Hassles

Step 3b				.20***

Gender * ethnic status	-.30	.28	-.06

School hassles	.35	.03	.35***

Predictor	B	SE B

Step 1

SES	.14	.03

City	.15	.04

5th grade	.08	.04

6th grade	.11	.04

Step 2

Gender	-.07	.03

Ethnic status	-.15	.03

Step 3a

Gender * ethnic status	-.60	.30

Mediator: School Hassles

Step 3b

Gender * ethnic status	-.30	.28

School hassles	.35	.03


Subtype	Location

A	Pancreatic duct into parenchyma∗

B	Pancreatic duct through parenchyma∗

C	Intrahepatic bile ducts into parenchyma∗∗

D	Intrahepatic bile ducts through parenchyma∗∗∗

pe	on

A	Pancreatic duct into parenchyma∗

B	Pancreatic duct through parenchyma∗

C	Intrahepatic bile ducts into parenchyma∗∗

D	Intrahepatic bile ducts through parenchyma∗∗∗


Group

BMP group

with pins (n = 2)

without pins (n = 3)

nonBMP group

with pins (n = 2)

without pins (n = 3)

Control group


Group	Pretest	Posttest	Adjusted mean

Chess	1.75 (1.34)	1.81 (1.69)	1.64


Haplotype	Frequencies	Patients/Deaths	HR (95% CI) a

TTGG	0.415	379/184	1.00

CTGA	0.408	373/170	0.90 (0.73–1.10)


Characteristic

age (years)

male (%)

current smokers (%)

BMI (kg/m2)

waist (cm)

hypertensive (%)

antihypertensive treatment (%)

total cholesterol (mmol/L)

HDL cholesterol (mmol/L)

triglycerides (mmol/L)

TC:HDL ratio

fasting glucose (mmol/L)

diabetes (%)

IGT (%)


	Cross-sectional		Longitudinal

	Overweight T1	School Sample	Overweight T1	Overweight T2

n	125	172	80	80

Age	6–16	7–17	6–16	7–18

	11.02 (SD = 2.41)	11.88 (SD = 2.45)	11.29 (SD = 2.29)	12.58 (SD = 2.26)

Sex	61 female	88 female	42 female	42 female

	64 male	84 male	38 male	38 male


	Wild type	CD4−/−

Eosinophilia(cells/mg of lung tissue) (as % of total white cells)	684 ± 132 (6.3 %)	648 ± 161 (4.3 %)

Neutrophilia(cells/mg of lung tissue) (as % of total white cells)	6443 ± 1048 (45.3 %)	7361 ± 2260 (49.1 %)

Tissue mono/macs(cells/mg of lung tissue) (as % of total white cells)	639 ± 132 (4.5 %)	686 ± 179 (9.4 %)

Alveolar macs(cells/mg of lung tissue) (as % of total white cells)	292 ± 48 (2.1 %)	241 ± 25 (1.6 %)

Mast cells (cells/slide)	66 ± 12	77 ± 10

	Wild type	CD4−/−

Eosinophilia(cells/mg of lung tissue) (as % of total white cells)	684 ± 132 (6.3 %)	648 ± 161 (4.3 %)

Neutrophilia(cells/mg of lung tiss	6443 ± 1048	7361 ± 2260 (49.1

ue) (as % of total white cells)	 (45.3 %)	 %)

Tissue mono/macs(cells/mg of lung tissue) (as % of total white cells)	639 ± 132 (4.5 %)	686 ± 179 (9.4 %)

Alveolar macs(cells/mg of lung tissue) (as % of total white cells)	292 ± 48 (2.1 %)	241 ± 25 (1.6 %)

Mast cells (cells/slide)	66 ± 12	77 ± 10


Line item category	Uganda per district (US$)	Kenya per district (US$)	% Uganda	% Kenya

Equipment	3,947	4,015	27.3	25.9

Consumables	502	91	3.5	0.6

 Salaries	5,860	8,753	40.6	56.4

 Per diems	20	84	0.1	0.5

Total personnel	5,880	8,837	40.7	57.0

 Fuel	1,426	316	9.9	2.0

 Maintenance	274	155	1.9	1.0

Total transport (excl. training)	1,700	472	11.8	3.0

Travel & accommodation (for training)	590	64	4.1	0.4

Utilities	623	797	4.3	5.1

Room rental	521	816	3.6	5.3

Fees	93	19	0.6	0.1

Other	585	401	4.1	2.6

TOTAL	14,439	15,512	100.0	100.0


Ref.	Age	Sex	Implementation period	Admission to hospital	Location	Type of plant	Approach to lesions	Healing time

2	64	M	12 h	Immediately	Left distal thigh	R. arvensis	Debridement, topical nitrofurantoin	3 weeks

3	17	M	48 h	2 days	Back, scrotum, penis, chest	R. arvensis	Wet dressing, silver sulfadiazine, collogenase	4 weeks

4	42	M	8 h	1 week	Left foot dorsum and ankle	C. testiculatus	Clorhexidine scrub + split thickness skin graft	7 days

	40	F	4 h	3 weeks	Right foot dorsum and ankle	C. testiculatus	Clorhexidine scrub + paraffin gauze	10 days

	60	F	2 h	10 days	Right foot dosrum and left knee	C. testiculatus	Clorhexidine scrub + paraffin gauze	7 days

	65	F	2 h	1 week	Left knee	C. testiculatus	Clorhexidine scrub+ paraffin gauze	15 days

	48	F	4 h	14 days	Right leg	C. falcatus	Clorhexidine scrub + paraffin gauze	2 weeks

5	52-76	F:6 M:3	12 h	NA	Both knees: 7 One knee: 2	R. constantinopolitanus	Topical antibacterial treatment	10 d

6	55	F	1 day	2 days	Right knee	R. illyricus	Wet dressing and topical antibiotics	4 days

7	58	F	2 days	5 days	Left knee	R. illyricus	Topical antibacterial cream	A few days

	54	F	1 days	3 days	Right knee	R. illyricus	Wet dressing and topical antibiotic	1 week

8	69	M	2.5 h	2 days	Left knee	C. falcatus	Wet dressing and topical fusidic acid	2 weeks

	33	F	1.5 h	2 days	Right distal leg, ankle, dorsal foot	C. falcatus	Wet dressing and topical antibiotic	3 weeks

	18	F	1 h	1 week	Left ankle, dorsal foot	C. falcatus	Wet dressing and topical antibiotic	2 weeks

9	47	F	25 min	NA	Right knee	C. falcatus	Wet dressing and topical mometasone cream	10 days

10	45	F	Overnight	2 days	Abdomen, right leg	R. damascenus	Wet dressing and topical fusidic acid	10 days

11	NA	F	NA	NA	Right ankle	C. falcatus	Wet dressing	2 weeks

Current	48	M	1 h	1 days	Right thumb	R. arvensis	Dressing with fusidic acid	3 weeks

	59	F	Overnight	3 days	Bilateral knee	R. arvensis	Clorhexidine scrub + silver sulfadiazine cream	2 weeks

	70	F	2 days	Immediately	Bilateral knee	R. arvensis	Clorhexidine scrub + silver sulfadiazine cream	10 days

Sex	Implementation period	Admission to hospital	Location	Type of plant	Approach to lesions	Healing time

M	12 h	Immediately	Left distal thigh	R. arvensis	Debridement, topical nitrofurantoin	3 weeks

M	48 h	2 days	Back, scrotum, penis, chest	R. arvensis	Wet dressing, silver sulfadiazine, collogenase	4 weeks

M	8 h	1 week	Left foot dorsum and ankle	C. testiculatus	Clorhexidine scrub + split thickness skin graft	7 days

F	4 h	3 weeks	Right foot dorsum and ankle	C. testiculatus	Clorhexidine scrub + paraffin gauze	10 days

F	2 h	10 days	Right foot dosrum and left knee	C. testiculatus	Clorhexidine scrub + paraffin gauze	7 days

F	2 h	1 week	Left knee	C. testiculatus	Clorhexidine scrub+ paraffin gauze	15 days

F	4 h	14 days	Right leg	C. falcatus	Clorhexidine scrub + paraffin gauze	2 weeks

F:6 M:3	12 h	NA	Both knees: 7 One knee: 2	R. constantinopolitanus	Topical antibacterial treatment	10 d

F	1 day	2 days	Right knee	R. illyricus	Wet dressing and topical antibiotics	4 days

F	2 days	5 days	Left knee	R. illyricus	Topical antibacterial cream	A few days

F	1 days	3 days	Right knee	R. illyricus	Wet dressing and topical antibiotic	1 week

M	2.5 h	2 days	Left knee	C. falcatus	Wet dressing and topical fusidic acid	2 weeks

F	1.5 h	2 days	Right distal leg, ankle, dorsal foot	C. falcatus	Wet dressing and topical antibiotic	3 weeks

F	1 h	1 week	Left ankle, dorsal foot	C. falcatus	Wet dressing and topical antibiotic	2 weeks

F	25 min	NA	Right knee	C. falcatus	Wet dressing and topical mometasone cream	10 days

F	Overnight	2 days	Abdomen, right leg	R. damascenus	Wet dressing and topical fusidic acid	10 days

F	NA	NA	Right ankle	C. falcatus	Wet dressing	2 weeks

M	1 h	1 days	Right thumb	R. arvensis	Dressing with fusidic acid	3 weeks

F	Overnight	3 days	Bilateral knee	R. arvensis	Clorhexidine scrub + silver sulfadiazine cream	2 weeks

F	2 days	Immediately	Bilateral knee	R. arvensis	Clorhexidine scrub + silver sulfadiazine cream	10 days


Baseline characteristics	Overall no. of patients (%)	Arm A (%)	Arm B (%)	Arm C (%)

Total	19	5	8	6

Age

 Median	60	51	57.5	61.5

 Range	27–86	27–71	50–86	47–77

Sex

 Male	6 (32)	1 (20)	4 (50)	1 (17)

 Female	13 (68)	4 (80)	4 (50)	5 (83)

ECOG Performance Status

 0	10	2	4	4

 1	9	3	4	2

Stage at Trial Entry

 No evidence of disease	4 (21)	2 (40)	0 (0)	2 (33)

 Locally advanced	1 (5)	0 (0)	0 (0)	1 (17)

 Metastatic*	14 (74)	3 (60)	8 (100)	3 (50)

Prior Therapy

 Chemotherapy alone	5	1	3	1

 Chemotherapy/RT alone	2	0	1	1

 Surgery total	12	4	4	4

Surgery followed by chemotherapy	7	3	2	2

5	1	2	2

Surgery followed by chemo/RT

Prior surgical resection

 Yes	12 (63)	4 (80)	4 (50)	4 (67)

 No	7 (37)	1 (20)	4 (50)	2 (33)

Serum CEA at trial initiation (ng/mL)

 Median	4.8	5.3	4.65	7.95

 Range	1–246.7	1.1–34.2	2.1–246.7	1–18.1

Serum CA-19-9 at trial initiation (ng/mL)

 Median	532	22	1067	27

 Range	3–96,900	3–2,710	3–96,900	3–30,300

Baseline characteristics	Overall no. of patients (%)	Arm A (%)	Arm B (%)	Arm C (%)

To		5

tal	19		8	6

Age

Median	60	51	57.5	61.5

Range	27–86	27–71	50–86	47–77

Sex

Male	6 (32)	1 (20)	4 (50)	1 (17)

Female	13 (68)	4 (80)	4 (50)	5 (83)

ECOG Performance Status

0	10	2	4	4

1	9	3	4	2

Stage at Trial Entry

No evidence of disease	4 (21)	2 (40)	0 (0)	2 (33)

Locally advanced	1 (5)	0 (0)	0 (0)	1 (17)

Metastatic*	14 (74)	3 (60)	8 (100)	3 (50)

Prior Therapy

Chemotherapy alone	5	1	3	1

Chemotherapy/RT alone	2	0	1	1

Surgery total	12	4	4	4

Surgery followed by chemotherapy	7	3	2	2

5	1	2	2

Surgery followed by chemo/RT

Prior surgical resection

Yes	12 (63)	4 (80)	4 (50)	4 (67)

No	7 (37)	1 (20)	4 (50)	2 (33)

Serum CEA at trial initiation (ng/mL)

Median	4.8	5.3	4.65	7.95

Range	1–246.7	1.1–34.2	2.1–246.7	1–18.1

Serum CA-19-9 at trial initiation (ng/mL)

Median	532	22	1067	27

Range	3–96,900	3–2,710	3–96,900	3–30,300


 Method 	 Precision 	 Recall 	F1

 SVM only 	 0.6 	 0.12 	 0.2

 With del+WkNN 	 0.7879 	 0.26 	 0.391

 With add+WkNN 	 0.66 	 0.33 	 0.44

 With del+SoftSL 	 0.2140 	 0.64 	 0.3208

 With add+SoftSL 	 0.4653 	 0.47 	 0.4677


	without hot compress	with hot compress

ICG-half-life [min]	5.88 ± 0.49	5.35 ± 0.5

k-value (%/min)	11.8 ± 1.0	13.0 ± 1.2

Room temperature [°C]	21.2 ± 0.8	22.1 ± 0.6

Skin temperature right upper abdomen [°C]	32.8 ± 0.9	40.6 ± 1.6

Heart rate [1/min]	68.0 ± 8.4	68.0 ± 11.0

Systolic blood pressure [mmHg]	132 ± 18	132 ± 21

Diastolic blood pressure [mmHg]	86 ± 11	87 ± 16

	without hot compress	with hot compress

Systolic blood pressure [mmHg]	132 ± 18	132 ± 21

Diastolic blood pressure [mmHg]	86 ± 11	87 ± 16


Management	All patients(n = 1,903)	Age ≥ 65 years(n = 975)	Age < 65 years(n = 928)

Other‡	36 (2)	13 (1)	23 (2)

Paralytic (%)

No paralytics	1,291 (68)	689 (71)	602 (65)

Rocuronium	402 (21)	177 (18)	225 (24)

Vecuronium	150 (8)	75 (8)	75 (8)

Succinylcholine	60 (3)	34 (3)	26 (3)

Specialty of first intubator (%)

Transitional year resident§	703 (37)	384 (39)	319 (34)

Emergency medicine resident	648 (34)	298 (31)	350 (39)

Emergency physician	348 (18)	180 (18)	168 (18)

Other specialties¶	202 (11)	113 (12)	89 (10)

Number of intubation attempts, median (IQR)	1(1–2)	1(1–2)	1 (1–2)

> 3 intubation attempts (%)	255 (13)	128 (13)	127 (14)

Ultimate intubation success (%)	5 (< 1)	3 (< 1)	2 (< 1)


siRNA name	sequence

A2-3UTR 1	5′-UUAAUUCUCUCCGUAGCUCCCCC-3′

A2-3UTR 2	5′-UCUUACUGUUCCAUUGGCCCCC-3′

A2-3UTR 3	5′-AUUAUCCUUAAGAACCUAGCCCCC-3′

A2-3UTR 4	5′-UUCUUACUGUUCCAUUGGCCCCC-3′

scrambled siRNA	5′-UAAGCACGAAGCUCAGAGUCCCCC-3′

siRNA name

A2-3UTR 1

A2-3UTR 2

A2-3UTR 3

A2-3UTR 4

scrambled siRNA

sequence

5′-UUAAUUCUCUCCGUAGCUCCCCC-3′

5′-UCUUACUGUUCCAUUGGCCCCC-3′

5′-AUUAUCCUUAAGAACCUAGCCCCC-3′

5′-UUCUUACUGUUCCAUUGGCCCCC-3′

5′-UAAGCACGAAGCUCAGAGUCCCCC-3′


	Number of patients (%)	Return of spontaneous circulation (n)	P value	Initial survival	Final survival

				n	P value	n	P value

Age			0.027		0.149		0.390

 <1 month	2 (4.5%)	1		0		0

 1–12 months	9 (20.4%)	2		2		0

 1–8 years	13 (29.5%)	10		5		0

 >8 years	20 (45.4%)	15		12		3

Gender			1		0.753		0.290

 Female	16 (36.3%)	18		6		0

 Male	28 (63.6%)	10		13		3

Site of arrest			0.827		1		0.693

 Home	6 (13.6%)	5		3		0

 Public place	13 (29.5%)	7		5		1

 Emergency Department	3 (6.8%)	2		1		0

 Pediatric intensive care unit	18 (40.9%)	11		8		1

 Other hospital areas	4 (9%)	3		2		1

Inhospital versus out-of hospital			1		1		1

 Inhospital	22 (50%)	14		10		2

 Out-of-hospital	22 (50%)	14		9		1

Diagnosis			0.256		0.484		.06

 Heart disease or arrhythmia	18 (40.9%)	13		9		2

 Respiratory disease	1 (2.2%)	1		1		1

 Neurological disease	8 (18.1%)	5		3		0

 Infectious disease	3 (6.8%)	2		1		0

 Drowning	4 (9%)	3		2		0

 Sudden infant death syndrome	4 (9%)	0		0		0

 Traumaa	1 (2.2%)	1		0		0

 Other	2 (4.5%)	1		1		0

 Unknown	3 (6.8%)	2		2		0

	Number of patients (%)	Return of spontaneous circulation (n)

Age

<1 month	2 (4.5%)	1

1–12 months	9 (20.4%)	2

1–8 years	13 (29.5%)	10

>8 years	20 (45.4%)	15

Gender

Female	16 (36.3%)	18

Male	28 (63.6%)	10

Site of arrest

Home	6 (13.6%)	5

Public place	13 (29.5%)	7

Emergency Department	3 (6.8%)	2

Pediatric intensive care unit	18 (40.9%)	11

Other hospital areas	4 (9%)	3

Inhospital versus out-of hospital

Inhospital	22 (50%)	14

Out-of-hospital	22 (50%)	14

Diagnosis

Heart disease or arrhythmia	18 (40.9%)	13

Respiratory disease	1 (2.2%)	1

Neurological disease	8 (18.1%)	5

Infectious disease	3 (6.8%)	2

Drowning	4 (9%)	3

Sudden infant death syndrome	4 (9%)	0

Traumaa	1 (2.2%)	1

Other	2 (4.5%)	1

Unknown	3 (6.8%)	2


Comorbidity	Classification by severity	PCs

		n	n (%)	p

Heart disease	surgical or interventional	19	5 (26)	0.26

	only medication	31	13 (42)

COPD	stage 3 or 4*	8	0 (0)	0.60

	stage 1 or 2	104	17 (16)

CNS disease	paralysis	8	2 (25)	0.69

	no paralysis	31	11 (35)

Liver disease	cirrhosis	8	5 (63)	0.16

	hepatitis	13	3 (23)

Renal dysfunction	dialysis	5	2 (40)	0.65

	no dialysis	49	15 (31)

Diabetes mellitus	regular use of insulin	16	4 (25)	0.46

	oral medication	51	8 (16)


1. Of three influenza reference strains provided to WHO (A/California/7/2009, A/California/4/2009 and A/Texas/5/2009) by NHRC and USAFSAM, the A/California/7/2009 was selected as the seed strain.

2. Two biosafety-level 3 (BSL-3) laboratories were commissioned in 2009 at NHRC in San Diego, Calif., and AFRIMS in Bangkok, Thailand; and two BSL-2 laboratories were commissioned, one at the University of Buea, Cameroon, and one on the campus of the Cameroonian Army installation in Yaoundé, Cameroon, under supervision of the Global Viral Forecasting Initiative.

3. NAMRU-3 partners reported the first definitive evidence of human cutaneous leishmaniasis from Leishmania major infections in Ghana.

4. AFRIMS published the first report of clinically significant Plasmodium falciparum malaria resistance to the potent artemisinin antimalarial drug class, spurring WHO, Bill & Melinda Gates Foundation and host national malaria control officials to institute aggressive measures to contain and eliminate artemisinin-resistant malaria in Southeast Asia.

5. The first documented cases of Venezuelan equine encephalitis, brucellosis, dengue and Q fever in Ecuador were reported by NMRCD-Lima, and the first laboratory-confirmed cases of leptospirosis in the border areas of Thailand and Myanmar were reported by AFRIMS.

6. AFRIMS provided timely outbreak response services to the Nepali National Public Health laboratory, ultimately characterizing (by pulse-field gel electrophoresis) nearly 6,000 cases of multidrug-resistant typhoid fever originating from a single point source, and uniformly quinolone-resistant.

7. NAMRU-3 worked closely with WHO to conduct novel A/H1N1 laboratory diagnostic training for 73 participants representing 32 different countries in a strategic and timely two-week period in May 2009.

8. NEPMU-2, NAMRU-3, and AFHSC collaboratively supported CENTCOM efforts in establishing in-theatre novel A/H1N1 testing and isolation of servicemembers deployed or deploying to sites around the world.

9. The WRAIR/USAMRU-K Malaria Diagnostics and Control Center of Excellence, established in 2003, having trained more than 600 malaria microscopists, established new malaria diagnostics training capabilities in Nigeria and Tanzania, leading to a visit by the president of Tanzania to WRAIR to establish new collaborations between the U.S. Army and Tanzania.

10. NMRCD, as part of its expansive febrile-disease surveillance network in the Amazon basin, published the first comprehensive study of the etiologies of undifferentiated febrile illness in Ecuador, documenting the first laboratory-confirmed cases of Venezualan equine encephalitis, brucellosis, dengue and Q fever in Ecuador.

1. Of three influenza reference strains provided to WHO (A/California/7/2009, A/California/4/2009 and A/Texas/5/2009) by NHRC and USAFSAM, the A/California/7/2009 was selected as the seed strain.

8. NEPMU-2, NAMRU-3, and AFHSC collaboratively supported CENTCOM efforts in establishing in-theatre novel A/H1N1 testing and isolation of servicemembers deployed or deploying to sites around the world.

9. The WRAIR/USAMRU-K Malaria Diagnostics and Control Center of Excellence, established in 2003, having trained more than 600 malaria microscopists, established new malaria diagnostics training capabilities in Nigeria and Tanzania, leading to a visit by the president of Tanzania to WRAIR to establish new collaborations between the U.S. Army and Tanzania.

10. NMRCD, as part of its expansive febrile-disease surveillance network in the Amazon basin, published the first comprehensive study of the etiologies of undifferentiated febrile illness in Ecuador, documenting the first laboratory-confirmed cases of Venezualan equine encephalitis, brucellosis, dengue and Q fever in Ecuador.


Protein	Description	Other Aliases

BOD1	biorientation of chromosomes in cell division 1	FAM44B

CENPW	centromere protein W	CUG2

CENPN	centromere protein N	CENP-N

CCNB2	cyclin B2	HsT17299

CDKN3	cyclin-dependent kinase inhibitor 3	KAP

CKS1B	CDC28 protein kinase regulatory subunit 1B	CKS1

CKS2	CDC28 protein kinase regulatory subunit 2	CKSHS2

ERH	enhancer of rudimentary homolog (Drosophila)	DROER

GMNN	geminin, DNA replication inhibitor	Gem

HAUS1	HAUS augmin-like complex, subunit 1	CCDC5

ITGB3BP	integrin beta 3 binding protein (beta3-endonexin)	CENPR

MAD2L1	MAD2 mitotic arrest deficient-like 1 (yeast)	MAD2

MAD2L2	MAD2 mitotic arrest deficient-like 2 (yeast)	MAD2B

MITD1	microtubule interacting and trafficking domain containing 1	_

NUP37	nucleoporin 37 kDa	p37

RAN	RAN, member RAS oncogene family	Gsp1

SPC25	SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae)	SPBC25

OIP5	Opa interacting protein 5	MIS18B

Protein	Description	Other Aliases

GMNN	geminin, DNA replication inhibitor	Gem

HAUS1	HAUS augmin-like complex, subunit 1	CCDC5

ITGB3BP	integrin beta 3 binding protein (beta3-endonexin)	CENPR

MAD2L1	MAD2 mitotic arrest deficient-like 1 (yeast)	MAD2

MAD2L2	MAD2 mitotic arrest deficient-like 2 (yeast)	MAD2B

MITD1	microtubule interacting and trafficking domain containing 1	_

NUP37	nucleoporin 37 kDa	p37

RAN	RAN, member RAS oncogene family	Gsp1

SPC25	SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae)	SPBC25

OIP5	Opa interacting protein 5	MIS18B


Tool	Method	Symbol	Ref.	Time/Gbase

FragGeneScan	Hidden Markov Model	FGS3,FGS5	[11]	6 hours

MetaGeneAnnotator	Codon usage + start site heuristics	MGA	[9]	15 min

MetaGeneMark	Codon usage + gc-content heuristics	MGM	[8]	20 min

Orphelia	Neural network	OPH	[10]	13 hours

Prodigal	Codon usage + dynamic programming	PRD	[12]	30 min

Tool	Method	Symbol	Ref.	Time/Gbase

MetaGeneAnnotator	Codon usage + start site heuristics	MGA	[9]	15 min

MetaGeneMark	Codon usage + gc-content heuristics	MGM	[8]	20 min

Orphelia	Neural network	OPH	[10]	13 hours

Prodigal	Codon usage + dynamic programming	PRD	[12]	30 min


Parameters	AM	PM	ABS Diff	% Error

Mean ± SD (max)	Mean ± SD (max)	Mean ± SD (max)	Mean ± SD (max)	P Value


		N =236	MV1	Validation Sample S-QoL 18 matched by age and gender N=236

1. Sociodemographics		N (%)	%	N (%)

Gender	Men	205 (86.9)	0.0	205 (86.9)

Age (years)	M (SD)2	37.9 (10.8)	0.0	37.9 (10.7)

Marital status	Single	218 (94.0)	1.7	NA6

2. Clinical characteristics	M(SD)2	%

MCSI3	Total score	21.6 (12.4)	18.6	NA

RAS4	Personal confidence and hope	31.7 (6.5)	20.8	NA

	Willingness to ask for help	10.0 (2.7)	8.9

	Goal and success orientation	19.4 (3.8)	7.2

	Reliance on others	13.6 (4.1)	12.3

	No domination by symptoms	8.9 (3.2)	11.0

SF-365	Physical Functioning	82.7 (26.4)	0.04	79.1 (22.1)

	Social Functioning	52.7 (33.5)	0.12	54.4 (29.0)

	Role—Physical Problems	74.6 (30.2)	0.12	43.9 (35.6)

	Role—Emotional Problems 	55.8 (33.4)	0.12	39.6 (41.7)

	Mental Health	48.2 (22.0)	0.12	57.2 (20.1)

	Vitality	44.0 (20.1)	0.12	48.4 (19.0)

	Bodily Pain	65.6 (32.6)	0.12	64.7 (27.0)

	General Health	54.4 (21.0)	0.12	54.8 (20.1)

	Mental composite score	34.7 (12.5)	0.12	37.3 (11.1)

	Physical composite score	51.4 (11.1)	0.12	46.9 (7.9)

		N =236	MV1	Validation Sample S-QoL 18 matched by age and gender N=236

1. Sociodemographics		N (%)	%	N (%)

Gender	Men	205 (86.9)	0.0	205 (86.9)

Age (years)	M (SD)2	37.9 (10.8)	0.0	37.9 (10.7)

Marital status	Single	218 (94.0)	1.7	NA6

2. Clinical characteristics	M(SD)2	%

MCSI3	Tota	21.6 (12	18.6	NA

		N =236	MV1	Validation Sample S-QoL 18 matched by age and gender N=236

	l score	.4)

RAS4	Personal confidence and hope	31.7 (6.5)	20.8	NA

	Willingness to ask for help	10.0 (2.7)	8.9

	Goal and success orientation	19.4 (3.8)	7.2

	Reliance on others	13.6 (4.1)	12.3

	No domination by symptoms	8.9 (3.2)	11.0

SF-365	Physical Functioning	82.7 (26.4)	0.04	79.1 (22.1)

	Social Functioning	52.7 (33.5)	0.12	54.4 (29.0)

	Role—Physical Problems	74.6 (30.2)	0.12	43.9 (35.6)

	Role—Emotional Problems	55.8 (33.4)	0.12	39.6 (41.7)

	Mental Health	48.2 (22.0)	0.12	57.2 (20.1)

	Vitality	44.0 (20.1)	0.12	48.4 (19.0)

	Bodily Pain	65.6 (32.6)	0.12	64.7 (27.0)

	General Health	54.4 (21.0)	0.12	54.8 (20.1)

	Mental composite score	34.7 (12.5)	0.12	37.3 (11.1)

	Physical composite score	51.4 (11.1)	0.12	46.9 (7.9)


Medium/Organism	Staphylococcus aureus	Staphylococcus epidermidis	Escherichia coli	Candida albicans

Mueller-Hinton agar	x	x	x	x

Blood agar	x	x	x

Blood agar-NaCl	x	x

CHROMagar Candida				x

Roosvelt-Park Institute Medium 1640 with L-glutamine	x	x	x	x

Sabouraud agar				x

Endo agar			x

Medium/Organism	Staphylococcus aureus	Staphylococcus epidermidis	Escherichia coli	Candida albicans

Mueller-Hinton agar	x	x	x	x

Blood agar	x	x	x

Blood agar-NaCl	x	x

CHROMagar Candida				x

Roosvelt-Park Institute Medium 1640 with L-glutamine	x	x	x	x

Sabouraud				x


Proposed legislation changes	<underline>Utilitarian</underline>	<underline>++</underline>	<underline>+</underline>	<underline>0</underline>	<underline>-</underline>	<underline>--</underline>	<underline>Rights-focused</underline>

Community supervision		<underline>x</underline>

Broad definition of mental disorder		<underline>x</underline>

Detention of DSPD		<underline>x</underline>

More general tribunal members				<underline>x</underline>

Communication amongst services		<underline>x</underline>

Overall assessment			<underline>x</underline>

Proposed legislation changes	Utilitarian	++	+

Community supervision		x

Broad definition of mental disorder		x

Detention of DSPD		x

More general tribunal members

Communication amongst services		x

Overall assessment			x


Variable	Percent (%)

Fitzpatrick skin score grades 4 and 5 	79

Using sunscreen	24.2

Exposure to direct sunlight <15 min/day	71

Milk and milk product (servings/day)

 None	23

 1 to 2	64

 3 to 4	9

 >4	4

Fortified breakfast cereal (servings/week)

 None	73.6

 1 to 2	12.8

 3 to 4	12

 >4	1.6

Fish (servings/week)

 None	23

 1 to 2	46.2

 3 to 4	25.3

 >4	5.5

Cod liver oil 	17.6

Vitamin D supplement 	24.2


Patient	Age	Clinical signs	Metal ions in peripheral blood	CRP (>5 mg/L)	White cell count (>10/nl)	Duration of implantation (years)	Articulating material

 	a) Chrome (>7 μg/L)

 	b) Cobalt (>7 μg/L)

Metallosis

1	62	Pain, osteolysis around cup on x-ray	a) 21.3 μg/L	2.3 mg/L	4.55/nl	8	Metal on metal

 	b) 37.6 μg/L

2	47	Pain	a) 17.7 μg/L	16.6 mg/L	8.96/nl	5	Metal on metal

 	b) 38.90 μg/L

3	42	Pain	a) 4.06 μg/L	3.6 mg/L	9.39/nl	6	Metal on metal

 	b) 5.49 μg/L

4	71	Pain	a) 15.0ug/L	6.9 mg/L	5.89/nl	6	Metal on metal

 	b) 30.0ug/L

5	60	Non	a) 43.0 μg/L	2.0 mg/L	5.70/nl	8	Metal on metal

 	b) 64.0 μg/L

Patient	Age	Clinical signs	CRP (>5 mg/l)	White cell count (>10/nl)	Duration of implantation (years)	Articulating material

Aseptic loosening

1	70	Pain, osteolysis around cup and stem on x-ray	17.3 mg/l	4.91/nl	19	Ceramic on polyethylene

2	71	Pain, osteolysis around stem on x-ray	10.0 mg/l	8.17/nl	3	Ceramic on polyethylene

3	75	Pain, osteolysis around cup on x-ray	2.0 mg/l	5.74/nl	15	Metal on polyethylene

4	59	Pain, osteolysis around stem on x-ray	2.0 mg/l	3.53/nl	2	Ceramic on polyethylene

5	81	Pain, osteolysis around stem on x-ray	2.0 mg/l	6.92/nl	12	Metal on polyethylene

6	84	Pain, osteolysis around stem on x-ray	2.0 mg/l	6.1/nl	6	Metal on polyethylene

Patient	Age	Clinical signs	Metal ions in peripheral blood	CRP (>5 mg/L)

	a) Chrome (>7 μg/L)

	b) Cobalt (>7 μg/L)

Metallosis

1	62	Pain, osteolysis around cup on x-ray	a) 21.3 μg/L	2.3 mg/L

	b) 37.6 μg/L

2	47	Pain	a) 17.7 μg/L	16.6 mg/L

	b) 38.90 μg/L

3	42	Pain	a) 4.06 μg/L	3.6 mg/L

	b) 5.49 μg/L

4	71	Pain	a) 15.0ug/L	6.9 mg/L

	b) 30.0ug/L

5	60	Non	a) 43.0 μg/L	2.0 mg/L

	b) 64.0 μg/L

Patient	Age	Clinical signs	CRP (>5 mg/l)

Aseptic loosening

1	70	Pain, osteolysis around cup and stem on x-ray	17.3 mg/l

2	71	Pain, osteolysis around stem on x-ray	10.0 mg/l

3	75	Pain, osteolysis around cup on x-ray	2.0 mg/l

4	59	Pain, osteolysis around stem on x-ray	2.0 mg/l

5	81	Pain, osteolysis around stem on x-ray	2.0 mg/l

6	84	Pain, osteolysis around stem on x-ray	2.0 mg/l

White cell count (>10/nl)	Duration of implantation (years)	Articulating material

4.55/nl	8	Metal on metal

8.96/nl	5	Metal on metal

9.39/nl	6	Metal on metal

5.89/nl	6	Metal on metal

5.70/nl	8	Metal on metal

White cell count (>10/nl)	Duration of implantation (years)	Articulating material

4.91/nl	19	Ceramic on polyethylene

8.17/nl	3	Ceramic on polyethylene

5.74/nl	15	Metal on polyethylene

3.53/nl	2	Ceramic on polyethylene

6.92/nl	12	Metal on polyethylene

6.1/nl	6	Metal on polyethylene


Antigen	Species	Source	Number	Dilution (Western)	Dilution (IHC)	Pepsin (IHC)

γ-2	Guinea pig	M. Watanabe	—	1:500	—	—

γ-2b	Rabbit	Cell Signaling Technology	8511	—	1:200	Yesc

γ-3	Guinea pig	M. Watanabe	—	1:500	—	—

γ-4	Rabbit	Abcam	ab81107	1:500	—	—

γ-5	Rabbit	M. Watanabe	—	1:500	—	—

γ-7	Rabbit	Frontiers Institute	Af720	1:500	1:500	No

γ-8	Rabbit	Frontiers Institute	Af1000	1:2000	1:1000	No

GluA1	Rabbit	Abcam	ab31232	—	1:500	Yes

GluA2	Mouse	Millipore	MAB397	1:500	1:500	Yes

c-Fos	Goat	Santa Cruz Biotechnology	sc-52-G	—	1:100	No

Actin	Mouse	Abcam	ab3280	1:5000	—	—

GFP	Chicken	Abcam	Ab13970	—	1:500	No

CGRPb	Mouse	Sigma	C7113	—	1:400	No

vGluT1b	Guinea pig	Synaptic Systems	135 304	—	1:400	No

vGluT2b	Guinea pig	Millipore	AB2251	—	1:4000	No

Antigen	Species	Source	Number	Dilution (Western)	Dilution (IHC)	Pepsin (IHC)

GluA1	Rabbit	Abcam	ab31232	—	1:500	Yes

GluA2	Mouse	Millipore	MAB397	1:500	1:500	Yes

c-Fos	Goat	Santa Cruz Biotechnology	sc-52-G	—	1:100	No

Actin	Mouse	Abcam	ab3280	1:5000	—	—

GFP	Chicken	Abcam	Ab13970	—	1:500	No

CGRPb	Mouse	Sigma	C7113	—	1:400	No

vGluT1b	Guinea pig	Synaptic Systems	135 304	—	1:400	No

vGluT2b	Guinea pig	Millipore	AB2251	—	1:4000	No


	PEmb-QoL questions	Number of items	Cronbach’s alpha	Average inter-item correlation (r)

Frequency of complaints	Q1	8	0.90	0.52

Activities of daily living limitations	Q4	13	0.95	0.60

Work-related problems	Q5	4	0.91	0.72

Social limitations	Q6	1	-	-

Intensity of complaints	Q7, Q8	2	0.70	0.54

Emotional complaints	Q9	10	0.92	0.52

PEmb-QoL summary score	Q1, Q4, Q5, Q6, Q7, Q8, Q9	38	0.92	0.44


Patient no.	Diagnosis	Source	PB-blast%	BM-blast%	WBC	FAB	Cytogenetics	Status

1	AML	PB	92	 	 	M1	OD	New

2	AML	PB	 	 	331.08	M1	CD34-ANLL	New

3	AML	PB	82	4.8	81.5	M2b	FLT-ITD	New

4	AML	PB	88	 	29.5	M1	CEBPA mutation; BCR-ABL(9;22)(+)	New

5	AML	PB	 	87.5	43.36	M5a	CBFβ/MYH11(+);BCR/ABL(-)	New

6	AML	PB	 	 	219.79	M1	BCR-ABL(9;22)(+), Ph (+)	New

7	AML	PB	52	 	4.64	M1	OD	New

8	AML	PB	92	 	53.48	M1	46XX[20] CD34-ANLL	Relapsed

9	AML	PB	98	 	156.9	M1	OD	New

10	AML	PB	96	 	143	M1	BCR/ABL	New

11	AML	PB	 	 	12.68	M2	OD	New

12	AML	PB	 	 	229	M1	OD	New

13	AML	PB	55	15.3	14.3	M1	OD	Relapsed

14	AML	PB	96	 	102.5	M1	OD	New

15	AML	PB	 	 	31.0	M1	OD	New

16	AML	PB	63.5	 	181.2	M0	TEL/AML1(+);C-Kit, NPM1, CEBPA, FLT3/ITD(-)	New

17	AML	PB	 	 	3.88	M3	PML-RARa(+)	Relapsed

18	AML	PB	 	>20	1.94	M6	OD	New

19	AML	PB	8	 	19.1	M5b	WT1(+)	New

20	AML	PB	 	<10	14.7	M5	FISH-t (15;17) PML-RARa (bcr3)	New

21	AML	PB	28	 	51.2	M2a	t(9;22) Bcr/abl (+); JAK2V617F(+) MLL/EVI1; MLL+	New

22	AML	PB	 	42	116.3	M4a	WT1 (+); FLT3-ILD (+)	Relapsed

23	AML	PB	 	24.5	77.4	M2b	FISH-AML/ETO (-); FLT3-ILD (+)	New

Patient no.	Diagnosis	Source	PB-blast%	BM-blast%

1	AML	PB	92

2	AML	PB

3	AML	PB	82	4.8

4	AML	PB	88

5	AML	PB		87.5

6	AML	PB

7	AML	PB	52

8	AML	PB	92

9	AML	PB	98

10	AML	PB	96

11	AML	PB

12	AML	PB

13	AML	PB	55	15.3

14	AML	PB	96

15	AML	PB

16	AML	PB	63.5

17	AML	PB

18	AML	PB		>20

19	AML	PB	8

20	AML	PB		<10

21	AML	PB	28

22	AML	PB		42

23	AML	PB		24.5

WBC	FAB	Cytogenetics	Status

	M1	OD	New

331.08	M1	CD34-ANLL	New

81.5	M2b	FLT-ITD	New

29.5	M1	CEBPA mutation; BCR-ABL(9;22)(+)	New

43.36	M5a	CBFβ/MYH11(+);BCR/ABL(-)	New

219.79	M1	BCR-ABL(9;22)(+), Ph (+)	New

4.64	M1	OD	New

53.48	M1	46XX[20] CD34-ANLL	Relapsed

156.9	M1	OD	New

143	M1	BCR/ABL	New

12.68	M2	OD	New

229	M1	OD	New

14.3	M1	OD	Relapsed

102.5	M1	OD	New

31.0	M1	OD	New

181.2	M0	TEL/AML1(+);C-Kit, NPM1, CEBPA, FLT3/ITD(-)	New

3.88	M3	PML-RARa(+)	Relapsed

1.94	M6	OD	New

19.1	M5b	WT1(+)	New

14.7	M5	FISH-t (15;17) PML-RARa (bcr3)	New

51.2	M2a	t(9;22) Bcr/abl (+); JAK2V617F(+) MLL/EVI1; MLL+	New

116.3	M4a	WT1 (+); FLT3-ILD (+)	Relapsed

77.4	M2b	FISH-AML/ETO (-); FLT3-ILD (+)	New